Current use of anti-infectives in dermatology

References

• Goldberg DM. The cephalosporins. Med. Clin. North Am. 71, 1113–1133 (1987).
   PubMed Web of Science ®Google Scholar
• Neu HC. The new β-lactamase-stable cephalosporins. Ann. Intern. Med. 97, 408–419 (1982).
   PubMed Web of Science ®Google Scholar
• Epstein ME, Amodio-Groton M, Sadick NS. Antimicrobial agents for the dermatologist. I. β-lactam antibiotics and related compounds. J. Am. Acad. Dermatol. 37, 149–165 (1997).
   PubMed Web of Science ®Google Scholar
• Sadick NS. Systemic antibiotic agents. Dermatol. Clinics 19, 1–21 (2001).
   PubMed Web of Science ®Google Scholar
• Johnson JD. The cephalosporins in dermatologic practice. Int. J. Dermatol. 25, 427–430 (1986).
   PubMed Web of Science ®Google Scholar
• Stewart C. Current management of common skin and soft tissue infections: cellulitis, folliculitis, mammalian bites, and puncture wounds – year 2001 update. Emergency Medicine Consensus Reports 1–16 (2001).
   Google Scholar
• McCarty J, Ruoff GE, Jacobson KD. Loracarbef (LY163892) versus cefaclor in the treatment of bacterial skin and skin-structure infections in an adult population. Am. J. Med. 92(Suppl. 6A), S80–S85 (1992).
   PubMed Web of Science ®Google Scholar
• Gordin FM, Wofsy CB, Mills J. Once-daily ceftriaxone for skin and soft tissue infections. Antimicrob. Agents Chemother. 27, 648–649 (1985).
   PubMed Web of Science ®Google Scholar
• Ison CA, Mouton JW, Jones K, Fenton KA, Livermore DM. Which cephalosporin for gonorrhoea? Sex. Transm. Infect. 80, 386–388 (2004).
   PubMed Web of Science ®Google Scholar
• Buening MK, Wold JS, Israel KS et al. Disulfiram-like reactions to β-lactams. J. Am. Med. Assoc. 245, 2027 (1981).
   Google Scholar
• Lopez AJ, O’Keefe PO, Morrissey M, Pickleman J. Ceftriaxone-induced cholelithiasis. Ann. Intern. Med. 115, 712–714 (1991).
   PubMed Web of Science ®Google Scholar
• Brittain DC. Erythromycin. Med. Clin. North Am. 71, 1147–1154 (1987).
   PubMed Web of Science ®Google Scholar
• Epstein ME, Amodio-Groton M, Sadick NS. Antimicrobial agents for the dermatologist. II. Macrolides, fluoroquinolones, rifamycins, tetracyclines, trimethoprim–sulfamethoxazole, and clindamycin. J. Am. Acad. Derm. 37, 365–381 (1997).
   PubMed Web of Science ®Google Scholar
• Bahal N, Nahata MC. The new macrolide antibiotics: azithromycin, clarithromycin, dirithromycin, and roxithromycin. Ann. Pharmacother. 26, 46–55 (1992).
   PubMed Web of Science ®Google Scholar
• Luft BJ, Dattwyler RJ, Johnson RC et al. Azithromycin compared with amoxicillin in the treatment of erythema migrans. A double-blind, randomized, controlled trial. Ann. Intern. Med. 124, 785–791 (1996).
   PubMed Web of Science ®Google Scholar
• Retsema A, Girard A, Schelkly W et al. Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against Gram-negative organsims. 31, 1939–1947 (1987).
   Google Scholar
• Bauernfeind A. In vitro activity of dirithromycin in comparison with other new and established macrolides. J. Antimicrob. Chemother. 31(Suppl. 3), 39–49 (1993).
   PubMed Web of Science ®Google Scholar
• Barry AL, Jones RN, Thornsberry C. In vitro activities of azithromycin (CP 62,993), clarithromycin (A-56268; TE-031), erythromycin, roxithromycin, and clindamycin. Antimicrob. Agents Chemother. 32, 752–754 (1988).
   PubMed Web of Science ®Google Scholar
• Dobson RL, Belknap BS. Topical erythromycin solution in acne. J. Am. Acad. Dermatol. 3, 478–482 (1980).
   PubMed Web of Science ®Google Scholar
• Lesher JL Jr, Chalker DK, Smith JG Jr et al. An evaluation of a 2% erythromycin ointment in the topical therapy of acne vulgaris. J. Am. Acad. Dermatol. 12, 526–531 (1985).
   PubMed Web of Science ®Google Scholar
• Lassus A. Comparative studies of azithromycin in skin and soft-tissue infections and sexually transmitted infections by neisseria and chlamydia species. J. Antimicrob. Chemother. 25(Suppl. A), 115–121 (1990).
   PubMed Web of Science ®Google Scholar
• Steingrimsson O, Olafsson JH, Thorarinsson H, Ryan RW, Johnson RB, Tilton RC. Azithromycin in the treatment of sexually transmitted disease. J. Antimicrob. Chemother. 25(Suppl. A), 109–114 (1990).
   PubMed Web of Science ®Google Scholar
• Kim Y-S, Yun H-J, Shim SK, Koo SH, Kim SY, Kim SA. Comparative trial of a single dose of azithromycin versus doxycycline for the treatment of mild scrub typhus. Clin. Infect. Dis. 39, 1329–1335 (2004).
   PubMed Web of Science ®Google Scholar
• Fernandez-Obregon AC. Azithromycin for the treatment of acne. Int. J. Dermatol. 39(1), 45–50 (2000).
   PubMed Web of Science ®Google Scholar
• Kapadia N, Talib A. Acne treated successfully with azithromycin. Int. J. Dermatol. 43, 766–767 (2004).
   PubMed Web of Science ®Google Scholar
• Bakar O, Demircay Z, Gurbuz O. Therapeutic potential of azithromycin in rosacea. Int. J. Dermatol. 43, 151–154 (2004).
   PubMed Web of Science ®Google Scholar
• Parish LC. Clarithromycin in the treatment of skin and skin structure infections: two multicenter clinical studies. Int. J. Dermatol. 32, 528–532 (1993).
   PubMed Web of Science ®Google Scholar
• Franck N, Cabie A, Villette B, Amor B, Lessana-Leibowitch M, Escande J-P. Treatment of Mycobacterium chelonae-induced skin infection with clarithromycin. J. Am. Acad. Dermatol. 28, 1019–1021 (1993).
   PubMed Web of Science ®Google Scholar
• Wasilewski MM, Wilson MG, Sides GD, Stotka JL. Comparative efficacy of 5 days of dirithromycin and 7 days of erythromycin in skin and soft tissue infections. J. Antimicrob. Chemother. 46, 255–262 (2000).
   PubMed Web of Science ®Google Scholar
• Clark G. Drug interactions and anti-infective therapies. Am. J. Med. 106, 227–237 (1999).
   PubMed Web of Science ®Google Scholar
• Piscitelli SC, Danziger LH, Rodvold KA. Clarithromycin and azithromycin: new macrolide antibiotics. Clin. Pharm. 11, 137–152 (1992).
   PubMedGoogle Scholar
• Amacher DE, Schomaker SJ, Retsema JA. Comparison of the effects of the new azalide antibiotic azithromycin and erythromycin estolate on rat liver cytochrome P-450. Antimicrob. Agents Chemother. 35, 1186–1190 (1991).
   PubMed Web of Science ®Google Scholar
• Lindstrom T, Hanssen B, Wrighton S. Cytochrome P450 complex formation by dirithromycin and other macrolides in rat and human livers. Antimicrob. Agents Chemother. 37, 265–269 (1993).
   PubMed Web of Science ®Google Scholar
• Hooper DC, Wolfson JS. Fluoroquinolone antimicrobial agents. N. Engl. J. Med. 324, 384–394 (1991).
   PubMed Web of Science ®Google Scholar
• Gentry LO. Therapy with newer oral β-lactam and quinolone agents for infections of the skin and skin structures: a review. Clin. Infect. Dis. 14, 285–297 (1992).
   PubMed Web of Science ®Google Scholar
• LaRosa SP, Tomecki KJ. Antibiotics: what’s new? Cutis 73(Suppl. 5), 10–14 (2004).
   PubMed Web of Science ®Google Scholar
• Tarshis GA, Miskin BM, Jones TM et al. Once-daily gatifloxacn versus oral levofloxacin in treatment of uncomplicated skin and soft tissue infections: double-blind, multicenter, randomized study. Antimicrob. Agents Chemother. 45, 2358–2362 (2001).
   PubMed Web of Science ®Google Scholar
• Parish LC, Routh HB, Miskin B et al. Moxifloxacin versus cephalexin in the treatment of uncomplicated skin infections. Int. J. Clin. Pract. 54, 497–503 (2001).
   Web of Science ®Google Scholar
• Schweiger ES, Weinberg JM. Novel antibacterial agents for skin and skin structure infections. J. Am. Acad. Dermatol. 50, 331–340 (2004).
   PubMed Web of Science ®Google Scholar
• Stein GE. Drug interactions with fluoroquinolones. Am. J. Med. 91 (Suppl. 6A), S81–S86 (1991).
   Web of Science ®Google Scholar
• Smith CR. The adverse effects of fluoroquinolones. J. Antimicrob. Chemother. 19, 709–712 (1987).
   PubMed Web of Science ®Google Scholar
• Fillastre JP, Leroy A, Moulin B et al. Pharmacokinetics of quinolones in real insufficiency. J. Antimicrob. Chemother. 26(Suppl. B), 51–60 (1990).
   PubMed Web of Science ®Google Scholar
• Saravolatz LD, Leggett J. Gatifloxacin, gemifloxacin, and moxifloxacin: the role of 3 newer fluoroquinolones. Clin. Infect. Dis. 37, 1210–1215 (2003).
   PubMed Web of Science ®Google Scholar
• Karchmer AW. Fluoroquinolone treatment of skin and skin structure infections. Drugs 58(Suppl. 2), 82–84 (1999).
   PubMed Web of Science ®Google Scholar
• Gentry LO. Review of quinolones in the treatment of infections of the skin and skin structure. J. Antimicrob. Chemother. 28(Suppl. C), 97–110 (1991).
   PubMed Web of Science ®Google Scholar
• Muijsers RBR, Jarvis B. Moxifloxacin. Drugs 62, 967–973 (2002).
   PubMed Web of Science ®Google Scholar
• Grasela TH, Dreis MW. An evaluation of the quinolone–theophylline interaction using the food and drug administration spontaneous sorting system. Arch. Intern. Med. 152, 617–621 (1992).
   PubMedGoogle Scholar
• Jolson HM, Tanner LA, Green L, Grasela TH Jr. Adverse reaction reporting of interaction between warfarin and fluoroquinolones. Arch. Intern. Med. 151, 1003–1004 (1991).
   PubMed Web of Science ®Google Scholar
• Lowe NJ, Fakouhi TD, Stern RS, Bourget T, Roniker B, Swabb EA. Photoreactions with a fluoroquinolone antimicrobial: evening versus morning dosing. Clin. Pharmacol. Ther. 56, 587–591 (1994).
   PubMed Web of Science ®Google Scholar
• Wijnands WJA, Vree TB, Van Herwaarden CLA. The influence of quinolone derivatives on theophylline clearance. Br. J. Clin. Pharmacol. 22, 677–683 (1986).
   PubMed Web of Science ®Google Scholar
• Baker SE, Hangii MC. Possible gatifloxacin-induced hypoglycemia. Ann. Pharmacother. 36, 1722–1726 (2002).
   PubMed Web of Science ®Google Scholar
• Donaldson AR, Vandiver JR, Finch CK. Possible gatifloxacin-induced hyperglycemia. Ann. Pharmacother. 38, 602–605 (2004).
   PubMed Web of Science ®Google Scholar
• Quigley CA, Lederman JR. Possible gatifloxacin-induced seizure. Ann. Pharmacother. 38, 235–237 (2004).
   PubMed Web of Science ®Google Scholar
• Ansari SR, Chopra N. Gatifloxacin and prolonged QT interval. Am. J. Med. Sci. 327(1), 55–56 (2004).
   PubMed Web of Science ®Google Scholar
• Tsankov NK, Kamarashev JA. Rifampin in dermatology. Int. J. Dermatol. 32, 401–406 (1993).
   PubMed Web of Science ®Google Scholar
• Sensi P. History of the development of rifampin. Rev. Infect. Dis. 5(Suppl. 3), S402–S406 (1983).
   PubMedGoogle Scholar
• Wehrli W. Rifampin: mechanisms of action and resistance. Rev. Infect. Dis. 59(Suppl. 3), S407–S411 (1983).
   Google Scholar
• Acocella G. Pharmacokinetics and metabolism of rifampin in humans. Rev. Infect. Dis. 5(Suppl. 3), S428–S432 (1983).
   PubMedGoogle Scholar
• Borcherdin SM, Baciewicz AM, Self TH. Update on rifampin drug interactions II. Arch. Intern. Med. 152, 711–716 (1992).
   PubMedGoogle Scholar
• Joshi RK, Nambiar PMK. Dermal leishmaniasis and rifampicin. Int. J. Dermatol. 28, 612–614 (1989).
   PubMed Web of Science ®Google Scholar
• Gamea AM, El-Tatawi FAY. The effect of rifampicin on rhinoscleroma: an electron microscopic study. J. Laryngol. Otol. 104, 772–777 (1990).
   PubMed Web of Science ®Google Scholar
• Hoss DM, Feder HM Jr. Addition of rifampin to conventional therapy for recurrent furunculosis. Arch. Dermatol. 131, 647–648 (1995).
   PubMedGoogle Scholar
• Wheat LJ, Kohler RB, White AL, White A. Effect of rifampin on nasal carriers of coagulase-positive staphylococci. J. Infect. Dis. 144, 177 (1981).
   Google Scholar
• Bachs L, Pares A, Elena M, Piera C, Rodes J. Effects of long-term rifampicin administration in primary biliary cirrhosis. Gastroenterology 102, 2077–2080 (1992).
   PubMed Web of Science ®Google Scholar
• Grosset J, Leventis S. Adverse effects of rifampin. Rev. Infect. Dis. 5, S440–S446 (1983).
   PubMedGoogle Scholar
• Klein NC, Cunha BA. Tetracyclines. Med. Clin. North Am. 79, 789–801 (1995).
   PubMed Web of Science ®Google Scholar
• Francke EL, Neu HC. Chloramphenicol and tetracyclines. Med. Clin. North Am. 71, 1155–1168 (1987).
   PubMed Web of Science ®Google Scholar
• Chaffins ML, Collison D, Fivenson DP. Treatment of pemphigus and linear IgA dermatosis with nicotinamide and tetracycline: a review of 13 cases. J. Am. Acad. Dermatol. 28, 998–1000 (1993).
   PubMed Web of Science ®Google Scholar
• Zemtsov A, Neldner KH. Successful treatment of dermatitis herpetiformis with tetracycline and nicotinamide in a patient unable to tolerate dapsone. J. Am. Acad. Dermatol. 28, 505–506 (1993).
   PubMed Web of Science ®Google Scholar
• Skidmore R, Kovach R, Walker C et al. Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne. Arch. Dermatol. 139, 459–464 (2003).
   PubMed Web of Science ®Google Scholar
• Cunliffe WJ, Grosshans E, Belaich S, Meynadier J, Alirezai M, Thomas LA. Comparison of the efficacy and safety of lymecycline and minocycline in patients with moderately severe acne vulgaris. Eur. J. Dermatol. 8, 161–166 (1998).
   PubMed Web of Science ®Google Scholar
• Neuvonen PJ, Pentilla O, Lehtovaara R et al. Effect of anti-epileptic drugs on the elimination of various tetracycline derivatives. Eur. J. Clin. Pharmacol. 9, 147 (1975).
   PubMed Web of Science ®Google Scholar
• Searcy RL, Simms MN, Foreman JA et al. Evaluation of the blood clotting mechanism in tetracycline-treated patients. Antimicrob. Agents Chemother. 4, 179 (1964).
   Google Scholar
• Bacon JF, Chenfield GM. Pregnancy attributable to interaction between tetracyclines and oral contraceptives. Br. Med. J. 280, 293 (1980).
   PubMed Web of Science ®Google Scholar
• Andersen WK, Feingold DS. Adverse drug interactions clinically important for the dermatologist. Arch. Dermatol. 131, 468–473 (1995).
   PubMed Web of Science ®Google Scholar
• Golub LM, Lee HM, Lehrer G et al. Minocycline reduces gingival collagenolytic activity during diabetes: preliminary observations and a proposed new mechanism of action. J. Periodontal. Res. 18, 516–526 (1983).
   PubMed Web of Science ®Google Scholar
• Golub LM, McNamara TF, D’Angelo G, Greenwald RA, Ramamurthy NS. A nonantibacterial chemically modified tetracycline inhibits mammalian collagenase activity. J. Dent. Res. 66, 1310–1314 (1987).
   PubMed Web of Science ®Google Scholar
• Golub LM, Lee HM, Ryan ME. Giannobile WV, Payne J, Sorsa T. Tetracyclines inhibit connective tissue breakdown by multiple nonantimicrobial mechanisms. Adv. Dent. Res. 12, 12–26 (1998).
   PubMedGoogle Scholar
• Schroeder K, Lee H, Wolff M, Ramamurthy N, Golub L. Low-dose tetracyclines (TCs) decreases elastas and β-glucuronidase activities in gingival crevicular fluid (GCF). J. Dent. Res. 69, 245 (1990).
   Google Scholar
• Schroeder KL, Ramamurthy NS, Szczepaneck KA et al. Low-dose doxycycline prevents attachment loss in adult periodontitis. J. Dent. Res. 71, 758 (1992).
   Google Scholar
• Periostat®, package insert. Collegenex Pharmaceuticals Inc., Newtown, PA, USA (2001).
   Google Scholar
• Shalita AR, Lee WL. Inflammatory acne. Dermatol. Clin. 1, 361–364 (1983).
   Web of Science ®Google Scholar
• Webster GF, McGinley KJ, Leyden JJ. Inhibition of lipase production in Propionibacterium acnes by subminimal-inhibitory concentrations of tetracycline and erythromycin. Br. J. Dermatol. 104, 453–457 (1981).
   PubMed Web of Science ®Google Scholar
• Webster GF, Leyden JJ, McGinley KJ, McArthur WP. Suppression of polymorphonuclear leukocyte chemotactic factor production in Propionibacterium acnes by subminimal-inhibitory concentrations of tetracycline, ampicillin, minocycline and erythromycin. Antimicrob. Agents Chemother. 21, 770–772 (1982).
   PubMed Web of Science ®Google Scholar
• Weinberg MA. New applications of doxycline hyclate in medicine & dentistry. US Pharm. (2004).
   Google Scholar
• Del Rosso JQ. A status report on the use of subantimicrobial-dose doxycycline: a review of the biologic and antimicrobial effects of the tetracyclines. Cutis 74, 118–122 (2004).
   PubMed Web of Science ®Google Scholar
• Bikowski JB. Subantimicrobiual dose doxycyclione for acne and rosacea. Skinmed. 1–12 (2003).
   Google Scholar
• Grossman ER, Walchek A, Freedman H. Tetracycline and permanent teeth: the relationship between doses and tooth involvement. Pediatrics 47, 567 (1971).
   PubMed Web of Science ®Google Scholar
• Guillon J-M, Joly P, Autran B, Denis M, Akoun G, Debre P, Mayaud C. Minocycline-induced cell-mediated hypersensitivity pneumonitis. Ann. Intern. Med. 117, 476–481 (1992).
   PubMed Web of Science ®Google Scholar
• Matsuura T, Shimizu Y, Fujimoto H, Miyazaki T, Kano S. Minocycline-related lupus. Lancet 340, 1553 (1992).
   PubMed Web of Science ®Google Scholar
• Katz J, Barak S, Shemer J, Langevitz P, Livneh A. Black tongue associated with minocycline therapy. Arch. Dermatol. 131, 620 (1995).
   PubMedGoogle Scholar
• Knowles SR, Shapiro L, Shear NH. Serious adverse reactions induced by minocycline. Arch. Dermatol. 132, 934–939 (1996).
   PubMed Web of Science ®Google Scholar
• Thibault M-J, Billick RC, Srolovitz H. Minocycline-induced sweet’s syndrome. J. Am. Acad. Dermatol. 27, 801–804 (1992).
   PubMed Web of Science ®Google Scholar
• Falagas ME, Gorbach SL. Clindamycin and metronidazole. Med. Clin. North Am. 79, 845–867 (1995).
   PubMed Web of Science ®Google Scholar
• Smilack JD, Wilson WR, Cockerill FR. Tetracyclines, chloramphenicol, erythromycin, clindamycin, and metronidazole. Mayo Clin. Proc. 66, 1270–1280 (1991).
   PubMed Web of Science ®Google Scholar
• Panzer JD, Brown DC, Epstein WL, Lipson RL, Mahaffey HW, Atkinson WH. Clindamycin levels in various body tissues and fluids. J. Clin. Pharmacol. 12, 259–262 (1972).
   Web of Science ®Google Scholar
• McGehee RF Jr, Smith CB, Wilcox C, Finland M. Comparative studies of antibacterial activity in vitro and absorption and excretion of lincomycin and clinimycin. Am. J. Med. Sci. 256, 279–292 (1968).
   PubMed Web of Science ®Google Scholar
• Klainer AS. Clindamycin. Med. Clin. North Am. 71, 1169–1175 (1987).
   PubMed Web of Science ®Google Scholar
• Klempner MS, Styrt B. Prevention of recurrent staphylococcal skin infections with low-dose oral clindamycin therapy. J. Am. Med. Assoc. 260, 2682–2685 (1988).
   PubMed Web of Science ®Google Scholar
• Becker LE, Bergstresser PR, Whiting DA et al. Topical clindamycin therapy for acne vulgaris. Arch. Dermatol. 117, 482–485 (1981).
   PubMed Web of Science ®Google Scholar
• Lookingbill DP, Chalker DK, Lindholm JS et al. Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel, and vehicle gel: combined results of two double-blind investigations. J. Am. Acad. Dermatol. 37, 590–595 (1997).
   PubMed Web of Science ®Google Scholar
• Ellis CN, Leyden J, Katz HI et al. Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis 67, 13–20 (2001).
   PubMed Web of Science ®Google Scholar
• Cunliffe WJ, Holland KT, Bojar R, Levy SF. A randomized, double-blind comparison of a clindamycin phosphate/benzoyl peroxide gel formulation and a matching clindamycin gel with respect to microbiologic activity and clinical efficacy in the topical treatment of acne vulgaris. Clin. Ther. 24, 1117–1133 (2002).
   PubMed Web of Science ®Google Scholar
• Wolf JE Jr, Kaplan D, Kraus SJ et al. Efficacy and tolerability of combined topical treatment of acne vulgaris with adapalene and clindamycin: a multicenter, randomized, investigator-blinded study. J. Am. Acad. Dermatol. 49, S211–S217 (2003).
   PubMed Web of Science ®Google Scholar
• Bartlett JG. Antimicrobial agents implicated in Clostridium difficile toxin-associated diarrhea or colitis. Johns Hopkins Med. J. 149, 6–9 (1981).
   PubMedGoogle Scholar
• Smilack JD. Trimethoprim–sulfametoxazole. Mayo Clin. Proc. 74, 730–734 (1999).
   PubMed Web of Science ®Google Scholar
• Hitchings GH. Mechanism of action of trimethoprim–sulfamethoxazole-I. J. Infect. Dis. 128(Suppl.), S433–S436 (1973).
   Google Scholar
• Burchall JJ. Mechanism of action of trimethoprim–sulfamethoxazole-II. J. Infect. Dis. 128(Suppl.), S437–S441 (1973).
   Google Scholar
• Cockerill FR, Edson RS. Trimethoprim–sulfamethoxazole. Mayo Clin. Proc. 66, 1260–1269 (1991).
   PubMed Web of Science ®Google Scholar
• Smego RA Jr, Moeller MB, Gallis HA. Trimethoprim–sulfamethoxazole therapy for nocardia infections. Arch. Intern. Med. 143, 711–718 (1983).
   PubMedGoogle Scholar
• Gold WL, Salit IE. Aeromonas hydrophila infections of skin and soft tissue: report of 11 cases and review. Clin. Infect. Dis. 16, 69–74 (1993).
   PubMed Web of Science ®Google Scholar
• Chaowagul W, Simpson AJH, Suputtamongkol Y, Smith MD, Angus BJ, White NJ. A comparison of chloramphenicol, trimethoprim–sulfamethoxazole, and doxycycline with doxycycline alone as maintenance therapy for melioidosis. Clin. Infect. Dis. 29, 375–380 (1999).
   PubMed Web of Science ®Google Scholar
• Margileth AM. Antibiotic therapy for cat-scratch disease: clinical study of therapeutic outcome in 268 patients and a review of the literature. Pediatr. Infect. Dis. J. 11, 474–478 (1992).
   PubMed Web of Science ®Google Scholar
• Cotterill JA, Cunliffe WJ, Williamson B. The effect of trimethoprim-sulphamethoxazole on sebum excretion rate and biochemistry in acne vulgaris. Br. J. Dermatol. 85, 130–133 (1971).
   PubMed Web of Science ®Google Scholar
• Floris-Moore MA, Amodio-Groton MI, Catalano MT. Adverse reactions to trimethoprim/sulfamethoxazole in AIDS. Ann. Pharmacother. 37, 1810–1813 (2003).
   PubMed Web of Science ®Google Scholar
• Alappan R, Perazella MA, Buller GK. Hyperkalemia in hospitalized patients treated with trimethoprim–sulfamethoxazole. Ann. Intern. Med. 124, 316–320 (1996).
   PubMed Web of Science ®Google Scholar
• Walker DC, Cohen PR. Trimethoprim–sulfamethoxazole-associated acute febrile neutrophilic dermatosis; case report and review of drug-induced sweet’s syndrome. J. Am. Acad. Dermatol. 34, 918–923 (1996).
   PubMed Web of Science ®Google Scholar
• Blumenfeld H, Cha J-H, Cudkowicz ME. Trimethoprim and sulfonamide-associated meningoencephalitis with MRI correlates. Neurology 46, 556–558 (1996).
   PubMed Web of Science ®Google Scholar
• Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI, and the Daptomycin 98–01 and 99–01 Investigators. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin. Infect. Dis. 38, 1673–1681 (2004).
   PubMed Web of Science ®Google Scholar
• Snydman DR, Jacobus NV, McDermott LA, Lonks JR, Boyce JM. Comparative in vitro activities of daptomycin and vancomycin against resistant Gram-positive pathogens. Antimicrob. Agents Chemother. 44, 3447–3450 (2000).
   PubMed Web of Science ®Google Scholar
• Moelering RC Jr. Linezolid: the first oxazolidinone antimicrobial. Ann. Intern. Med. 138, 135–142 (2003).
   PubMed Web of Science ®Google Scholar
• Dresser LD, Rybak M. The pharmacologic and bacteriologic properties of oxazolidinones, a new class of synthetic antimicrobials. Pharmacotherapy 18, 456–462 (1998).
   PubMed Web of Science ®Google Scholar
• Plouffe JF. Emerging therapies for serious Gram-positive bacterial infections: a focus on linezolid. Clin. Infect. Dis. 31(Suppl. 4), S144–S149 (2000).
   PubMed Web of Science ®Google Scholar
• Green SL, Maddox JC, Huttenbach ED. Linezolid and reversible myelosuppression. J. Am. Med. Assoc. 285, 1291 (2001).
   PubMed Web of Science ®Google Scholar
• Stevens DL, Smith LG, Bruss JB et al. Randomized comparison of linezolid (PNU-100766) versus oxacillin–dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob. Agents Chemother. 44, 3408–3413 (2000).
   PubMed Web of Science ®Google Scholar
• Moellering RC Jr. A novel antimicrobial agent joins the battle against resistant bacteria. Ann. Intern. Med. 130, 155–157 (1999).
   PubMed Web of Science ®Google Scholar
• Raghavan M, Linden PK. Newer treatment options for skin and soft tissue infections. Drugs 64, 1621–1642 (2004).
   PubMed Web of Science ®Google Scholar
• Aumercier M, Bouhallab S, Capmau M-L, Le Goffic F. RP 59500: a proposed mechanism for its bactericidal activity. J. Antimicrob. Chemother. 30(Suppl. A), 9–14 (1992).
   PubMed Web of Science ®Google Scholar
• Bergeron M, Montay G. The pharmacokinetics of quinupristin/dalfopristin in laboratory animals and humans. J. Antimicrob. Chemother. 39(Suppl. A), 129–138 (1997).
   PubMed Web of Science ®Google Scholar
• Drew RH, Perfect JR, Srinath L, Kurkimilis E, Dowzicky M, Talbot GH. Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin–dalfopristin in patients intolerant of or failing prior therapy. J. Antimicrob. Agents Chemother. 46, 775–784 (2000).
   Google Scholar
• Seltzer E, Dorr MB, Goldstein BP, Perry M, Dowell JA, Henkel T, and the Dalbavancin Skin and Soft-Tissue Infection Study Group. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin. Infect. Dis. 37, 1298–1303 (2003).
   PubMed Web of Science ®Google Scholar
• Candiani G, Abbondi M, Borgonovi M, Romano G, Parenti F. In vitro and in vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic. J. Antimicrob. Chemother. 44, 179–192 (1999).
   PubMed Web of Science ®Google Scholar
• Zeckel ML, Preston DA, Allen BS. In vitro activities of LY333328 and comparative agents against nosocomial Gram-positive pathogens collected in a 1997 global surveillance study. Antimicrob. Agents Chemother. 44, 1370–1374 (2000).
   PubMed Web of Science ®Google Scholar
• Harland S, Tebbs E, Elliott TSJ. Evaluation of the in vitro activity of the glycopeptide antibiotic LY333328 in comparison with vancomycin and teicoplanin. J. Antimicrob. Chemother. 41, 273–276 (1998).
   PubMed Web of Science ®Google Scholar
• Milatovic D, Schmitz F-J, Verhoef J, Fluit AC. Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates. Antimicrob. Agents Chemother. 47, 400–404 (2003).
   PubMed Web of Science ®Google Scholar
• Postier RG, Green SL, Klein SR, Ellis-Grosse EJ, Loh E. Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. Clin. Ther. 26, 704–714 (2004).
   PubMed Web of Science ®Google Scholar
• Goldstein EJC, Reinhardt JF, Murray PM, Finegold SM. Outpatient therapy of bite wounds: demographic data, bacteriology, and a prospective, randomized trial of amoxicillin/clavulanic acid versus penicillin +/- dicloxacillin. Int. J. Dermatol. 26, 123–127 (1987).
   PubMed Web of Science ®Google Scholar
• Keating MR. Antiviral agents for non-human immunodeficiency virus infections. Mayo Clin. Proc. 74, 1266–1283 (1999).
   PubMed Web of Science ®Google Scholar
• Brown TJ, Vander Straten M, Tyring SK. Antiviral agents. Dermatol. Clin. 19(1), 23–34 (2001).
   PubMed Web of Science ®Google Scholar
• Darby G. Acyclovir and beyond. J. Int. Med. Res. 22(Suppl. 1), A33–A42 (1994).
   Web of Science ®Google Scholar
• Brown TJ, McCrary M, Tyring SK. Antiviral agents: nonantiviral drugs. J. Am. Acad. Dermatol. 47, 581–599 (2002).
   PubMed Web of Science ®Google Scholar
• Acosta EP, Fletcher CV. Valacyclovir. Ann. Pharmacother. 31, 185–191 (1997).
   PubMed Web of Science ®Google Scholar
• Nilsen AE, Aasen T, Halsos AM et al. Efficacy of oral acyclovir in the treatment of initial and recurrent genital herpes. Lancet 2, 571–573 (1982).
   PubMed Web of Science ®Google Scholar
• Reichman RC, Badger GJ, Mertz GJ, Corey L, Richman DD, Connor JD et al. Treatment of recurrent genital herpes simplex infections with oral acyclovir: a controlled trial. J. Am. Med. Assoc. 251(16), 2103–2107 (1984).
   PubMed Web of Science ®Google Scholar
• Spruance SL, Nett R, Marbury T, Wolff R, Johnson J, Spaulding T. Acyclovir cream for treatment of herpes simplex labialis: results of two randomized, double-blind, vehicle-controlled, multicenter clinical trials. Antimicrob. Agents Chemother. 46, 2238–2243 (2002).
   PubMed Web of Science ®Google Scholar
• Cohen JI. Recent advances in varicella-zoster virus infection. Ann. Intern. Med. 130, 922–932 (1999).
   PubMed Web of Science ®Google Scholar
• Wallace MR, Bowler WA, Murray NB, Brodine SK, Oldfield EC III. Treatment of adult varicella with oral acyclovir: a randomized, placebo-controlled trial. Ann. Intern. Med. 117, 358–363 (1992).
   PubMed Web of Science ®Google Scholar
• Huff JC, Bean B, Balfour HH Jr et al. Therapy of herpes zoster with oral acyclovir. Am. J. Med. 85(Suppl. 2A), 84–89 (1988).
   PubMed Web of Science ®Google Scholar
• Wood MJ, Kay R, Dworkin RH, Soong S-J, Whitley RJ. Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta-analysis of placebo-controlled trials. Clin. Infect. Dis. 22, 341–347 (1996).
   PubMed Web of Science ®Google Scholar
• Liesegang TJ. Diagnosis and therapy of herpes zoster ophthalmicus. Ophthalmology 98, 1216–1229 (1991).
   PubMed Web of Science ®Google Scholar
• Cobo LM, Foulks GN, Liesegang T et al. Oral acyclovir in the treatment of acute herpes zoster ophthalmicus. Ophthalmology 93, 763–770 (1986).
   PubMed Web of Science ®Google Scholar
• Harding SP, Porter SM. Oral acyclovir in herpes zoster ophthalmicus. Curr. Eye Res. 10, 177–182 (1991).
   PubMed Web of Science ®Google Scholar
• Van Landingham KE, Marsteller HB, Ross GW, Hayden FG. Relapse of herpes simplex encephalitis after conventional acyclovir therapy. J. Am. Med. Assoc. 259(7), 1051–1053 (1988).
   PubMed Web of Science ®Google Scholar
• Brown TJ, Vander Straten M, Tyring SK. Antiviral agents. Dermatol. Clin. 19(1), 23–34 (2001).
   PubMed Web of Science ®Google Scholar
• Spruance SL, Tyring SK, DeGregorio B, Miller C, Beutner K, and the Valaciclovir Study Group. A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Arch. Intern. Med. 156, 1729–1735 (1998).
   Google Scholar
• Reitano M, Tyring S, Lang W et al., and the Internaional Valaciclovir HSV Study Group. Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. J. Infect. Dis. 178, 603–610 (1996).
   Web of Science ®Google Scholar
• Beutner KR, Friedman DJ, Forszpaniak C, Andersen PL, Wood MJ. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob. Agents Chemother. 39, 1546–1553 (1995).
   PubMed Web of Science ®Google Scholar
• Weinberg A, Bate BJ, Masters HB et al. In vitro activities of penciclovir and acyclovir against herpes simplex virus types 1 and 2. Antimicrob. Agents Chemother. 36, 2037–2038 (1992).
   PubMed Web of Science ®Google Scholar
• Spruance SL, Rea TL, Thoming C, Tucker R, Saltzman R, Boon R. Penciclovir cream for the treatment of herpes simplex labialis. A randomized, multicenter, double-blind, placebo-controlled trial. J. Am. Med. Assoc. 277, 1374–1379 (1997).
   PubMed Web of Science ®Google Scholar
• Raborn GW, Martel AY, Lassonde M, Lewis MAO, Boon R, Spruance SL. Effective treatment of herpes simplex labialis with penciclovir cream. Combined results of two trials. J. Am. Dent. Assoc. 133, 303–309 (2002).
   PubMed Web of Science ®Google Scholar
• Spruance SL, Rowe NH, Raborn GW, Thibodeau EA, D’Ambrosio JA, Bernstein DI. Peroral famciclovir in the treatment of experimental ultraviolet radiation-induced herpes simplex labialis: a double-blind, dose-ranging, placebo-controlled, multicenter trial. J. Infect. Dis. 179, 303–310 (1999).
   PubMed Web of Science ®Google Scholar
• Sacks SL, Aoki FY, Diaz-Mitoma F, Sellors J, Shafran SD. Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes: a randomized, double-blind multicenter trial. J. Am. Med. Assoc. 276, 44–49 (1996).
   PubMed Web of Science ®Google Scholar
• Diaz-Mitoma F, Sibbald RG, Shafran SD, Boon R, Saltzman RL. Oral famciclovir for the suppression of recurrent genital herpes. a randomized controlled trial. J. Am. Med. Assoc. 280, 887–892 (1998).
   PubMed Web of Science ®Google Scholar
• Tyring S, Barbarash RA, Nahlik JE et al, and the Collaborative Famciclovir Herpes Zoster Study Group. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. a randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 123, 89–96 (1995).
   PubMed Web of Science ®Google Scholar
• Gross G. Therapy of human papillomavirus infection and associated epithelial tumors. Intervirology 40, 368–377 (1997).
   PubMed Web of Science ®Google Scholar
• Conant MA. Immunomodulatory therapy in the management of viral infections in patients with HIV infection. J. Am. Acad. Dermatol. 43, S27–S30 (2000).
   Google Scholar
• Dockrell DH, Kinghorn GR. Imiquimod and resiquimod as novel immunomodulators. J. Antimicrob. Chemother. 48, 751–755 (2001).
   PubMed Web of Science ®Google Scholar
• Arican O, Guneri F, Bilgic K, Karaoglu A. Topical imiquimod 5% cream in external anogenital warts: a randomized, double-blind, placebo-controlled study. J. Dermatol. 31, 627–631 (2004).
   PubMed Web of Science ®Google Scholar
• Wallace MR, Chamberlin CJ, Sawyer MH et al. Treatment of adult varicella with sorivudine: a randomized, placebo-controlled trial. J. Infect. Dis. 174, 249–255 (1996).
   PubMed Web of Science ®Google Scholar
• Keam SJ, Chapman TM, Figgit DP. Brivudin (bromovinyl deoxyuridine). Drugs 64, 2091–2097 (2004).
   PubMed Web of Science ®Google Scholar
• Drake LA, Dinehart SM, Farmer ER et al. Guidelines of care for superficial mycotic infections of the skin: tinea corporis, tinea cruris, tinea faciei, tinea manuum, and tinea pedis. J. Am. Acad. Dermatol. 34, 282–286 (1996).
   PubMed Web of Science ®Google Scholar
• Ryder NS. Terbinafine: mode of action and properties of the squalene epoxidase inhibitors. Br. J. Dermatol. 126, 2–7 (1992).
   PubMed Web of Science ®Google Scholar
• Hazen KC. Fungicidal versus fungistatic activity of terbinafine and itraconazole: an in vitro comparison. J. Am. Acad. Dermatol. 38(5), S37–S41 (1998).
   PubMed Web of Science ®Google Scholar
• Leyden J. Pharmacokinetics and pharmacology of terbinafine and itraconazole. J. Am. Acad. Dermatol. 35(5), S42–S47 (1998).
   Google Scholar
• Balflour JA, Faulds D. Terbinafine. A review of its pharmacodynamic and pharmakinetic properties, and theraputic potential in superficial mycoses. Drugs 43(2), 259–284 (1992).
   PubMed Web of Science ®Google Scholar
• Jensen JC. Clinical pharmacokinetics of terbinafine (Lamisil). Clin. Exp. Dermatol. 14, 110–113 (1989).
   PubMed Web of Science ®Google Scholar
• Lever LR, Dykes PJ, Thomas R et al. How orally administered Terbinafine reaches the stratum corneum. J. Dermatol. Treat. 1, 23–25 (1990).
   Google Scholar
• Faergemann J, Zehender H, Jones T et al. Terbinafine levels in serum, stratum corneum, dermis-epidermis (without stratum corneum), hair, sebum, and eccrine sweat during and after 250 mg terbinafine orally in men. J. Invest. Dermatol. 24, 523 (1994).
   Google Scholar
• Vickers AE, Sinclair JR, Zollinger M et al. Multiple cytochrome P-450s involved in the metabolism of terbinafine suggest a limited potential for drug–drug interactions. Drug Metab. Dispos. 27(9), 1029–1038 (1999).
   PubMed Web of Science ®Google Scholar
• Sais G, Juggla A, Peryi J. Prevalence of dermatophyte onychomycosis in Spain: a cross-sectional study. Br. J. Dermatol. 132, 758–761 (1995).
   PubMed Web of Science ®Google Scholar
• Roberts DT. Prevalence of dermatophyte onychomycosis in the United Kingdom: results of an omnibus survey. Br. J. Dermatol. 126(39), 23–27 (1992).
   PubMed Web of Science ®Google Scholar
• Heikkila H, Stubb S. The prevalence of onychomycosis in Finland. Br. J. Dermatol. 133, 699–703 (1995).
   PubMed Web of Science ®Google Scholar
• Heikkila H, Stubb S. Long-term results in patients with terbinafine or itraconazole. Br. J. Dermatol. 146(2), 250–253 (2002).
   PubMed Web of Science ®Google Scholar
• Schatz F, Brautigam M, Dobrowolski E et al. Nail incorporation kinetics of terbinafine in onychomycosis patients. Clin. Exp. Dermatol. 20, 377–383 (1995).
   PubMed Web of Science ®Google Scholar
• Smith EB, Stein LF, Fivenson DP, Atillasoy ES. Clinical trial: the safety of terbinafine in patients over the age of 60 years: a multicenter trial in onychomycosis of the feet. Int. J. Dermatol. 39(11), 861–864 (2000).
   PubMed Web of Science ®Google Scholar
• Gupta AK, Konnikov N, Lynde CW. Single-blind, randomized, prospective study on terbinafine and itraconazole in the for the treatment of dermatophyte toenail onychomycosis in the elderly. J. Am. Acad. Dermatol. 44(3), 479–484 (2001).
   PubMed Web of Science ®Google Scholar
• Herranz P, Garcia J, De Lucas R et al. Toenail onychomycosis in patients with acquired immune deficiency syndrome: treatment with terbinafine. Br. J. Dermatol. 137(4), 577–580 (1997).
   PubMed Web of Science ®Google Scholar
• Cribier BJ, Bakshi. Terbinafine in the treatment of onychomycosis: a review of its efficacy in high-risk populations and in patients with nondermatophyte infections. Br. J. Dermatol. 150, 414–420 (2004).
   PubMed Web of Science ®Google Scholar
• McClellan KJ, Wiseman LR, Markmham A. Terbinafine. An update of its use in superficial mycoses. Drugs 58(1), 179–202 (1999).
   PubMed Web of Science ®Google Scholar
• Evans EG, Sigurgeirsson B. Double blind, randomized study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. The LION study group. Br. Med. J. 318, 1031–1035 (1999).
   PubMed Web of Science ®Google Scholar
• Sigurgeirsson B, Olafsson JH, Steinsson JB et al. Long-term effectiveness of treatment with terbinafine vs. itraconazole in onychomycosis: a 5-year blinded prospective follow-up study. Arch. Dermatol. 138(3), 353–357 (2002).
   PubMed Web of Science ®Google Scholar
• Haugh M, Helou S, Boissel JP, Cribier BJ. Terbinafine in fungal infections of the nails: a meta-analysis of randomized clinical trials. Br. J. Dermatol. 147(1), 118–121 (2002).
   PubMed Web of Science ®Google Scholar
• De Cutper C, Hindryckx PHFB. Long-term outcomes in the treatment of toenail onychomycosis. Br. J. Dermatol. 141(56), 15–20 (1999).
   PubMed Web of Science ®Google Scholar
• Warshaw EM, Bowman T, Bodman MA et al. Satisfaction with onychomycosis treatment. Pulse versus continuous dosing. J. Am. Podiatr. Med. Assoc. 93(5), 373–379 (2003).
   PubMed Web of Science ®Google Scholar
• Brautigam M, Nolting S, Scopf RE, Weidinger G. Randomized double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection. Seventh Lamisil German Onychomycosis Study Group. Br. Med. J. 311, 919–922 (1995).
   PubMed Web of Science ®Google Scholar
• De Backer M, De Vroey C, Lesaffre E et al. Twelve weeks of continuous oral therapy for toenail onychomycosis caused by dermatophytes: a double-blind comparative trial of terbinafine 250 mg/day versus itraconazole 200 mg/day. J. Am. Acad. Dermatol. 38(5 Pt 3), S57–S63 (1998).
   PubMed Web of Science ®Google Scholar
• Degreef H, del Palacio A, Mygind S et al. Randomized double-blind comparison of short-term itraconazole and terbinafine therapy for toenail onychomycosis. Acta Derm. Venereol. 79(3), 221–223 (1999).
   PubMed Web of Science ®Google Scholar
• Drake LA, Shear NH, Arlette JP et al. Oral terbinafine in the treatment of toenail onychomycosis: North American multicenter trial. J. Am. Acad. Dermatol. 37(5), 740–745 (1997).
   PubMed Web of Science ®Google Scholar
• Zaias N, Rebell G. The successful treatment of Trichophyton rubrum nail bed (distal subungual) onychomycosis with intermittent pulse-dosed terbinafine. Arch. Dermatol. 140(6), 691–695 (2004).
   PubMed Web of Science ®Google Scholar
• Tosti A, Piraccini BM, Stinchi C, Venturo N, Bardazzi F, Colombo MD. Treatment of dermatophyte nail infections: an open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy. J. Am. Acad. Dermatol. 34, 595–600 (1996).
   PubMed Web of Science ®Google Scholar
• Alpsoy E, Yilmaz E, Basaran E. Intermittent therapy with terbinafine for dermatophyte toe-onychomycosis: a new approach. J. Dermatol. 23, 259–262 (1996).
   PubMedGoogle Scholar
• Gupta AK, Lynde CW, Konnikov N. Single-blind, randomized prospective study of sequential itraconazole and terbinafine pulse compared with terbinafine pulse for the treatment of toenail onychomycosis. J. Am. Acad. Dermatol. 44, 485–491 (2001).
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman SM, Nahata MC. Oral terbinafine: a new antifungal agent. Ann. Pharmacother. 31(4), 445–446 (1997).
   PubMed Web of Science ®Google Scholar
• Segal R, Kritzman A, Cividalli L et al. Treatment of candida nail infection with terbinafine. J. Am. Acad. Dermatol. 35(6), 958–961 (1996).
   PubMed Web of Science ®Google Scholar
• Gupta AK, Gregurek-Novak T. Efficacy of itraconazole, terbinafine, fluconazole, griseofulvin, and ketoconazole in the treatment of Scopulariopsis brevicaulis causing onychomycosis of the toes. Dermatology 202(3), 235–238 (2001).
   PubMed Web of Science ®Google Scholar
• Gupta AK, Gregurek-Novak T, Konnikov N et al. Itraconazole and terbinafine treatment of some nondermatophyte molds causing onychomycosis of the toes and a review of the literature. J. Cutan. Med. Surg. 5(3), 206–210 (2001).
   PubMed Web of Science ®Google Scholar
• Lebwohl MG, Daniel CR, Leyden J et al. Efficacy and safety of terbinafine for nondermatophyte and mixed nondermatophyte and dermatophyte toenail onychomycosis. Int. J. Dermatol. 40(5), 358–360 (2001).
   PubMed Web of Science ®Google Scholar
• Gupta AK, Shear NH. Terbinafine: an update. J. Am. Acad. Dermatol. 37(6), 979–988 (1997).
   PubMed Web of Science ®Google Scholar
• Denning DW, Evans EGV, Kibbler CC et al. Fungal nail disease: a guide to good practice (report of a working group of the British Society for Medical Mycology). Br. Med. J. 311, 1277–1281 (1995).
   PubMed Web of Science ®Google Scholar
• Binder M, Nell G. Oral terbinafine (Lamisil) in the short-term treatment of fungal infections of the skin: results of a post-marketing surveillance study. Mycoses 42(9–10), 555–558 (1999).
   PubMed Web of Science ®Google Scholar
• White JE, Perkins PJ, Evans EG. Successful 2-week treatment with terbinafine (Lamisil) for moccasin tinea pedis and tinea manuum. Br. J. Dermatol. 123(3), 260–262 (1991).
   Google Scholar
• Savin RC. Oral terbinafine versus griseofulvin in the treatment of moccasin-type tinea pedis. J. Am. Acad. Dermatol. 23(4 Pt 2), 807–809 (1990).
   PubMed Web of Science ®Google Scholar
• Barnetson RS, Marley J, Bullen M et al. Comparison of one week of oral terbinafine (250 mg/day) with four weeks of treatment with clotrimazole 1% cream in interdigital tinea pedis. Br. J. Dermatol. 139(4), 675–678 (1998).
   PubMed Web of Science ®Google Scholar
• Scaparro E, Quadri G, Virno G et al. Evaluation of the efficacy and tolerability of oral terbinafine (Daskil) in patients with seborrheic dermatitis. A multicentre, randomized, investigator-blinded, placebo-controlled trial. Br. J. Dermatol. 144, 854–857 (2001).
   PubMed Web of Science ®Google Scholar
• Villars V, Jones T. Clinical efficacy and tolerability of terbinafine (Lamisil) – a new and systemic fungicidal treatment of dermatomycoses. Clin. Exp. Dermatol. 14, 124–127 (1989).
   PubMed Web of Science ®Google Scholar
• Jung EG, Haas PJ, Brautigham M et al. Systemic treatment of skin candidiasis: a randomized comparison of terbinafine and ketoconazole. Mycoses 37, 361–365 (1994).
   PubMed Web of Science ®Google Scholar
• Elewski BE. Treatment of tinea capitis: beyond griseofulvin. J. Am. Acad. Dermatol. 40(6 Pt 2), S27–S30 (1999).
   Google Scholar
• Gupta AK, Adam P, Dlova N et al. Theraputic options for the treatment of tinea capitis caused by Trichophyton species: griseofulvin versus the new oral antifungal agents, terbinafine, itraconazole, and fluconazole. Pediatr. Dermatol. 18(5), 433–438 (2001).
   PubMed Web of Science ®Google Scholar
• Silm H, Karelson M. Terbinafine: efficacy and tolerability in young children with tinea capitis due to microsporum canis. J. Eur. Acad. Dermatol. Venereol. 16(3), 228–230 (2002).
   PubMed Web of Science ®Google Scholar
• Lipozencic J, Skerlev M, Orofino-Costa R et al. A randomized, double-blind, parallel-group, duration-finding study of oral terbinafine and open-label, high-dose griseofulvin in children with tinea capitis due to microsporum species. Br. J. Dermatol. 146(5), 816–823 (2002).
   PubMed Web of Science ®Google Scholar
• Caceres-Rios H, Rueda M, Ballona R, Bustamante B. Comparison of terbinafine and griseofulvin in the treatment of tinea capitis. J. Am. Acad. Dermatol. 42(1 Pt 1), 80–84 (2000).
   PubMed Web of Science ®Google Scholar
• Koumantaki E, Kakourou T, Ralli E et al. Double dose of oral terbinafine is required for Microsporum canis tinea capitis. Pediatr. Dermatol. 18(4), 339–342 (2001).
   PubMed Web of Science ®Google Scholar
• Gupta AK, Sibbald RG, Lynde CW et al. Onychomycosis in children: prevalence and treatment strategies. J. Am. Acad. Dermatol. 36, 395–402 (1997).
   PubMed Web of Science ®Google Scholar
• Hay RJ. Theraputic potential of terbinafine in subcutaneous and systemic mycoses. Br. J. Dermatol. 141(56), 36–40 (1999).
   PubMed Web of Science ®Google Scholar
• Hull PR, Vismer HF. Treatment of cutaneous sporotrichosis with terbinafine. Br. J. Dermatol. 126, 51–55 (1992).
   PubMed Web of Science ®Google Scholar
• Gip L. Black piedra: the first case treated with terbinafine (Lamisil). Br. J. Dermatol. 130, 26–28 (1994).
   PubMed Web of Science ®Google Scholar
• Chapman SW, Pappas P, Kauffmann C et al. Comparative evaluation of the efficacy and safety of two doses of terbinafine (500 and 100 mg day) in the treatment of cutaneous or lymphocutaneous sporotrichosis. Mycoses 47(1–2), 62–68 (2004).
   PubMed Web of Science ®Google Scholar
• Sullivan DPO. Terbinafine: tolerability in general medical practice. Br. J. Dermatol. 141(56), 21–25 (1999).
   PubMed Web of Science ®Google Scholar
• Challa A, Suvannasankha A, Nayere Z, Santiago M. Terbinafine-associated hepatotoxicity. Am. J. Med. Sci. 325(5), 292–295 (2003).
   PubMed Web of Science ®Google Scholar
• Gupta AK, Shear NH. A risk–benefit assessment of the newer oral antifungal agents used to treat onychomycosis. Drug Saf. 22(1), 33–52 (2000).
   PubMed Web of Science ®Google Scholar
• Pauluzzi P, Boccucci N. Inverse psoriasis induced by terbinafine. Acta Derm. Venereol. 79(5), 389 (1999).
   PubMed Web of Science ®Google Scholar
• Shapiro M, Li LJ, Miller J. Terbinafine-induced neutropenia. Br. J. Dermatol. 140(6), 1196–1997 (1999).
   PubMed Web of Science ®Google Scholar
• Grunwald MH. Thrombocytopenia associated with oral terbinafine. Int. J. Dermatol. 37(8), 634 (1998).
   Google Scholar
• Papa CA, Miller OF. Pustular psoriasiform eruption with leukocytosis associated with terbinafine. J. Am. Acad. Dermatol. 39(1), 115–117 (1998).
   PubMed Web of Science ®Google Scholar
• O’sullivan DP, Needham CA, Bangs A et al. Postmarketing surveillance of oral terbinafine in the UK: report of a large cohort study. Br. J. Clin. Pharmacol. 42(5), 559–565 (1996).
   PubMed Web of Science ®Google Scholar
• Murphy M, Barnes L. Terbinafine-induced lupus erythematosus. Br. J. Dermatol. 138(4), 708–709 (1998).
   PubMed Web of Science ®Google Scholar
• Gupta AK, Soori GS, Del Rosso JQ, Bartos PB, Shear NH. Severe neutropenia associated with oral terbinafine therapy. J. Am. Acad. Dermatol. 38(5 Pt 1), 765–767 (1998).
   PubMed Web of Science ®Google Scholar
• Torrens JK, McWhinney PH. Parotid swelling and terbinafine. Br. Med. J. 316, 440–441 (1997).
   Google Scholar
• Kempinaire A, De Raeve L, Merckx M, De Coninck A, Bauwens M, Roseeuw D. Terbinafine-induced acute generalized exanthematuous pustulosis confirmed by a positive patch-test result. J. Am. Acad. Dermatol. 37(4), 653–655 (1997).
   PubMed Web of Science ®Google Scholar
• Gupta AK, Sibbald RG, Knowles SR, Lynde CW, Shear NH. Terbinafine therapy may be associated with the development of psoriasis de novo or its exacerbation: four case reports and a review of drug-induced psoriasis. J. Am. Acad. Dermatol. 36(5 Pt 2), 858–862 (1997).
   PubMed Web of Science ®Google Scholar
• Stricker BH, Van Riemsdijk MM, Sturkenboom MC, Ottervanger JP. Taste loss to terbinafine: a case-control study of potential risk factors. Br. J. Clin. Pharmacol. 42(3), 313–318 (1996).
   PubMed Web of Science ®Google Scholar
• Gupta AK, Gonder JR, Shear NH, Dilworth GR. The development of green vision in association with terbinafine therapy. Arch. Dermatol. 132(7), 845–846 (1996).
   PubMedGoogle Scholar
• Munn SE, Russell Jones R. Terbinafine and fixed drug eruption. Br. J. Dermatol. 133(5), 815–816 (1995).
   PubMed Web of Science ®Google Scholar
• Wach F, Stolz W, Hein R, Landthaler M. Severe erythema annulare centrifugum-like psoriatic drug eruption induced by terbinafine. Arch. Dermatol. 131(8), 960–961 (1995).
   PubMed Web of Science ®Google Scholar
• Todd P, Halpern S, Munro DD. Oral terbinafine and erythema multiforme. Clin. Exp. Dermatol. 20(3), 247–248 (1995).
   PubMed Web of Science ®Google Scholar
• Kovacs MJ, Alshammari S, Guenther L, Bourcier M. Neutropenia and pancytopenia associated with oral terbinafine. J. Am. Acad. Dermatol. 31(5 Pt 1), 806 (1994).
   PubMed Web of Science ®Google Scholar
• Carstens J, Wendelboe P, Sogaard H, Thestrup-Pedersen K. Toxic epidermal necrolysis and erythema multiforme following therapy with terbinafine. Acta Derm. Venereol. 74(5), 391–392 (1994).
   PubMed Web of Science ®Google Scholar
• Rzany B, Mockenhaupt M, Gehring W, Schopf E. Stevens–Johnson syndrome after terbinafine therapy. J. Am. Acad. Dermatol. 30(3), 509 (1994).
   PubMed Web of Science ®Google Scholar
• Teraki Y, Shiohara T. Spontaneous tolerance to terbinafine-induced lichenoid drug eruption. Dermatology 208(1), 81–82 (2004).
   PubMed Web of Science ®Google Scholar
• Lombardo M, Cerati M, Pazzaglia A. Acute generalized exanthematuous pustulosis induced by terbinafine. J. Am. Acad. Dermatol. 49(1), 158–159 (2003).
   PubMed Web of Science ®Google Scholar
• Taberner R, Puig L, Gilaberte M, Alomar A. Acute generalized exanthematous pustulosis induced by terbinafine. Eur J. Dermatol. 13(3), 313–314 (2003).
   PubMed Web of Science ®Google Scholar
• Zapata Garrido AJ, Romo AC, Padilla FB. Terbinafine hepatotoxicity. A case report and review of literature. Ann. Hepatol. 2(1), 47–51 (2003).
   PubMedGoogle Scholar
• Ajit C, Suvannasankha A, Zaeri N, Munoz SJ. Terbinafine-associated hepatotoxicity. Am. J. Med. Sci. 325(5), 292–295 (2003).
   PubMed Web of Science ®Google Scholar
• Hill VA, Chow J, Cowley N, Marsden RA. Subacute lupus erythematosus-like eruption due to terbinafine: report of three cases. Br. J. Dermatol. 148(5), 1056 (2003).
   PubMed Web of Science ®Google Scholar
• Szepietowski JC. Terbinafine exacerbates psoriasis: case report with a literature review. Acta Derm. Venereol. Croat. 11(1), 17–21 (2003).
   PubMedGoogle Scholar
• Anania FA, Rabin L. Terbinafine hepatotoxicity resulting in chronic biliary ductopenia and portal fibrosis. Am. J. Med. 112(9), 741–742 (2002).
   PubMed Web of Science ®Google Scholar
• Richert B, Uhoda I, De la Brassinne M. Hair loss after terbinafine treatment. Br. J. Dermatol. 145(5), 842 (2002).
   Google Scholar
• Lemont H, Sabo M. Terbinafine-associated taste disturbance with normal taste threshold scores. J. Am. Podiatr. Med. Assoc. 91(10), 540–541 (2001).
   PubMed Web of Science ®Google Scholar
• Callen JP, Hughes AP, Kulp-Shorten C. Subacute cutaneous lupus erythematosus induced or exacerbated by terbinafine: a report of 5 cases. Arch. Dermatol. 137(9), 1196–1198 (2001).
   PubMedGoogle Scholar
• Conjeevaram G, Vongthavaravat V, Sumner R, Koff RS. Terbinafine-induced hepatitis and pancytopenia. Dig. Dis. Sci. 46(8), 1714–1716 (2001).
   PubMed Web of Science ®Google Scholar
• van Puijenbroek EP, Egberts AC, Meyboom RH, Leufkens HG. Association between terbinafine and arthralgia, fever and urticaria: symptoms or syndrome? Pharmacoepidemiol. Drug Saf. 10(2), 135–142 (2001).
   PubMed Web of Science ®Google Scholar
• Chitturi S, Farrell GC. Drug-induced cholestasis. Semin. Gastrointest. Dis. 12(2), 113–124 (2001).
   PubMedGoogle Scholar
• Weaver TD, Jespersen DL. Multiple onychocryptosis following treatment of onychomycosis with oral terbinafine. Cutis 66(3), 211–212 (2001).
   Web of Science ®Google Scholar
• Aksalkal BA, Ozsoy E, Arnavit O, Ali Gurer M. Oral terbinafine-induced bullous pemphigoid. Ann. Pharmacother. 37(11), 1625–1627 (2003).
   PubMed Web of Science ®Google Scholar
• Gupta AK, Katz I, Shear NH. Drug interactions with itraconazole, fluconazole, and terbinafine and their management. J. Am. Acad. Dermatol. 41(2), 237–245 (1999).
   PubMed Web of Science ®Google Scholar
• Katz HI. Drug interactions of the newer oral antifungals. Br. J. Dermatol. 141(56), 26–32 (1999).
   PubMed Web of Science ®Google Scholar
• Smith EB. The treatment of dermatophytosis: safety considerations. J. Am. Acad. Dermatol. 43, S113–S119 (2000).
   PubMed Web of Science ®Google Scholar
• Shapiro LE, Shear NH. Drug interactions: proteins, pumps, and P-450s. J. Am. Acad. Dermatol. 47(4), 467–484 (2002).
   PubMed Web of Science ®Google Scholar
• Madani S, Barilla D, Cramer J, Wang Y, Paul C. Effect of terbinafine on the pharmacokinetics and pharmacodynamics of desipramine in healthy volunteers identified as cytochrome P450 2D6 (CYP 2D6) extensive metabolizers. J. Clin. Pharmacol. 42(11), 1211–1218 (2002).
   PubMed Web of Science ®Google Scholar
• O’Reardon JP, Hetznecker JM, Rynn MA, Baldassano CF, Szuba MP. Desipramine toxicity with terbinafine. Psychiatry 159(6), 1076 (2002).
   Google Scholar
• Van Der Kuy PH, Van Den Heuvel HA, Kempen RW, Vanmolkot LM. Pharmacokinetic interaction between nortriptyline and terbinafine. Ann. Pharmacother. 36(11), 1712–1714 (2002).
   PubMed Web of Science ®Google Scholar
• Goeteyn V, Naeyaert JM, Lambert J et al. Is systemic autoimmune disease a risk factor for terbinafine-induced erythema multiforme? Br. J. Dermatol. 142(3), 578 (2000).
   PubMed Web of Science ®Google Scholar
• Lovell MO, Speer KV, Havana RD, Sharkey FE. Histological changes resembling acute rejection in a liver transplant patient treated with terbinafine. Hum. Pathol. 34(2), 187–189 (2003).
   PubMed Web of Science ®Google Scholar
• Hair M, Bryson HM, GAO KL. Itraconazole. A reappraisal of its pharmacological properties and theraputic use in the management of superficial fungal infections. Drugs 51, 585–620 (1996).
   PubMed Web of Science ®Google Scholar
• Drug Information for the Health Care Professional, USP DI, The United States Pharmacopeial Convention, Inc., 17 Edition. Rand McNally, MA, USA, 296–308 (1997).
   Google Scholar
• Lomaestro BM, Piatek MA. Update on drug interactions with azole antifungal agents. Ann. Pharmacother. 32, 915–928 (1998).
   PubMed Web of Science ®Google Scholar
• Neuvonen PJ, Jalava K-M. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin. Pharmacol. Ther. 60, 54–61 (1996).
   PubMed Web of Science ®Google Scholar
• Lees RS, Lees AM. Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole. N. Engl. J. Med. 333, 664–665 (1995).
   PubMed Web of Science ®Google Scholar
• Horn M. Coadministration of itraconazole with hypolipidemic agents may induce rhabdomyolysis in healthy individuals. Arch. Dermatol. 132, 1254 (1996).
   Google Scholar
• Segaert MF, de Soete C, Vandewiele I, Verbanck. Drug-interaction-induced rhabdomyolysis. Nephrol. Dial. Transplant. 11, 1846–1847 (1996).
   PubMed Web of Science ®Google Scholar
• von Moltke LL, Greenblatt DJ, Grassi JM et al. Protease inhibitors as inhibitors of human cytochrome P450: high risk associated with ritonavir. J. Clin. Pharmacol. 38, 106–111 (1998).
   PubMed Web of Science ®Google Scholar
• De Wit S, Debier M, De Smet M et al. Effect of fluconazole on indinavir pharmacokinetics in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 42, 223–227 (1998).
   PubMed Web of Science ®Google Scholar
• Cato A III, Cao G, Hsu A et al. Evaluation of the effect of fluconazole on the pharmacokinetics of ritonavir. Drug Metab. Dispos. 25, 1104–1106 (1996).
   Web of Science ®Google Scholar
• Borin MT, Cox SR, Herman BD et al. Effect of fluconazole on the steady-state pharmacokinetics of delaverdine in human immunodeficiency virus-positive patients. Antimicrob. Agents Chemother. 41, 1892–1897 (1997).
   PubMed Web of Science ®Google Scholar
• Neuvonen PJ, Suhonen R. Itaconazole interacts with felodipine. J. Am. Acad. Dermatol. 33, 134–135 (1995).
   PubMed Web of Science ®Google Scholar
• Jalava KM, Olkkola KT, Neuvonen PJ. Itraconazole greatly increases plasma concentrations and effects of felodipine. Clin. Pharmacol. Ther. 61, 410–415 (1997).
   PubMed Web of Science ®Google Scholar
• Tailor SA, Gupta AK, Walter SE, Shear NH. Peripheral edema due to nifedipine–itraconazole interaction: a case report. Arch. Dermatol. 132, 350–352 (1996).
   PubMed Web of Science ®Google Scholar
• Fluconazole, package insert. Pfizer, Roerig, NY, USA, February (1997).
   Google Scholar
• Verspeelt J, De Doncker P, Groen K et al. Tolerability and safety of itraconazole in diabetics. Australas. J. Dermatol. 39(Suppl.), 290 (1997).
   Google Scholar
• Troglitazone (Rezulin®) product information. Parke-Davis, NJ, USA, January (1997).
   Google Scholar
• Acarbose (Precose®) product information. Bayer Corp, CT, USA, March (1998).
   Google Scholar
• Metformin (Glucophage®) product information. Bristol-Meyers Squibb Company, NJ, USA, June (1996).
   Google Scholar
• Repaglinide (Prandin®) product information. NovoNordisk Pharmaceuticals, NJ, USA, December (1997).
   Google Scholar
• Gumbleton M et al. Tolbutamide pharmacokinetics, in the presence of otraconazol, in the rat. J. Pharm. Pharmacol. 39(Suppl.), 150 (1987).
   PubMed Web of Science ®Google Scholar
• Glimepiride (Amaryl®) prescribing information. Hoechst-Roussel Pharmaceuticals, MO, USA, November (1996).
   Google Scholar
• Canafax DM, Graves NM, Hilligoss DM et al. Increased cyclosporin levels as a result of simultaneous fluconazole and cyclosporin therapy in renal transplant recipients: a double-blind, randomized pharmacokinetic and safety study. Transplant. Proc. 23, 1041 (1991).
   PubMed Web of Science ®Google Scholar
• Kramer MR, Marshall SE, Denning DW et al. Cyclosporin and itraconazole interaction in heart and lung transplant recipients. Ann. Intern. Med. 113, 327–329 (1990).
   PubMed Web of Science ®Google Scholar
• Back DJ, Tija JF. Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole, and terbinafine on the metabolism of cyclosporin by human liver microsomes. Br. J. Clin. Pharmacol. 32, 624–626 (1991).
   PubMed Web of Science ®Google Scholar
• Shaw MA, Gumbleton M, Nicholls PJ. Interaction of cyclosporin and itraconazole. Lancet 2, 637 (1987).
   PubMed Web of Science ®Google Scholar
• Wassmann, Nickineg G, Bohm M. Long QT syndrome and torsade de pointes in a patient receiving fluconazole. Ann. Intern. Med. 131(10), 797 (1999).
   PubMed Web of Science ®Google Scholar
• De Ponti F, Poluzzi E, Montanaro N. QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience. Eur. J. Clin. Pharmacol. 56, 1–18 (2000).
   PubMed Web of Science ®Google Scholar
• Tatro DS. Drug Interaction Facts. Facts and Comparisons. St Louis MO, USA, 536 (1999).
   Google Scholar
• Lefebvre RA, Van Peer A, Woestenborghs R. Influence of itraconazole on the pharmacokinetics and electrocardiographic effects of astemizole. Br. J. Clin. Pharmacol. 43, 319–322 (1997).
   PubMed Web of Science ®Google Scholar
• Crane JK, Shih HT. Syncope and cardiac arrhythmia due to an interaction between itraconazole and terbinafine. Am. J. Med. 95, 445–446 (1993).
   PubMed Web of Science ®Google Scholar
• Honig PK, Wortham DC, Hull R et al. Itraconazole affects single-dose terfinadine pharmacokinetics and cardiac repolarization pharmacodynamics. J. Clin. Pharmacol. 33, 1201–1206 (1993).
   PubMed Web of Science ®Google Scholar
• Cantilena LR, Sorrels S, Wiley T, Wortham D. Fluconazole alters terfinadine pharmacokinetics and electrocardiographic pharmacodynamics. Clin. Pharmacol. Ther. 57, 185 (1995).
   Google Scholar
• Gupta AK, Tomas E. New antifungal agents. Dermatol. Clin. 21(3), 565–576 (2003).
   PubMed Web of Science ®Google Scholar
• Van Cauteren H, Lampo A, Vandenberghe J et al. Safety aspects of oral antifungal agents. Br. J. Clin. Pract. Suppl. 71, 47–49 (1990).
   PubMedGoogle Scholar
• Borgers M, Van den Bossche H, De Brabander M. The mechanism of action of the new antimycotic ketoconazole. Am. J. Med. 74(1B), 2–8 (1983).
   PubMedGoogle Scholar
• Brown C, Caro I, Condry P. Multicenter clinical evaluation of ketoconazole in the treatment of cutaneous fungal infections. Cutis 33(6), 578–581 (1984).
   PubMed Web of Science ®Google Scholar
• Sohn CA. Evaluation of ketoconazole. Clin. Pharm. 1(3), 217–224 (1982).
   PubMedGoogle Scholar
• Garcia Rodriguez LA, Duque A, Castellsague J et al. A cohort study on the risk of acute liver injury among users of ketoconazole. Br. J. Clin. Pharmacol. 48(6), 847–852 (1999).
   PubMed Web of Science ®Google Scholar
• Chien RN, Yang LJ, Lin PY, Liaw YF. Hepatic injury during ketoconazole therapy in patients with onychomycosis: a controlled cohort study. Hepatology 25(1), 103–107 (1997).
   PubMed Web of Science ®Google Scholar
• Van Cauteren H, Lampo A, Vandenberghe J et al. Toxicological profile and safety evaluation of antifungal azole derivatives. Mycoses 32(Suppl. 1), 60–66 (1989).
   PubMed Web of Science ®Google Scholar
• Garcia Rodriguez LA, Dugue A, Castellsague J et al. A cohort study on the risk of acute liver injury amoung users of ketoconazole and other antifungal drugs. Br. J. Clin. Pharm. 48, 847–852 (1999).
   PubMed Web of Science ®Google Scholar
• Chien R, Yang L, Lin P, Liaw Y. Hepatic injury during ketoconazole therapy in patients with onychomycosis: a controlled cohort study. Hepatology 25(1), 103–107 (1997).
   PubMed Web of Science ®Google Scholar
• Fernandez-Nava HD, Laya-Cuadra B, Tianco EA. Comparison of single dose 400 mg versus 10-day 200 mg daily dose ketoconazole in the treatment of tinea versicolor. Int. J. Dermatol. 37(1), 77 (1998).
   Google Scholar
• Bhogal CS, Singal A, Baruah MC. Comparative efficacy of ketoconazole and fluconazole in the treatment of pityriasis versicolor: a one year follow-up study. J. Dermatol. 28(10), 535–539 (2001).
   PubMed Web of Science ®Google Scholar
• Farschian M, Yaghoobi R, Samadi K. Fluconazole versus ketoconazole in the treatment of tinea versicolor. J. Dermatol. Treat. 13(2), 73–76 (2002).
   PubMed Web of Science ®Google Scholar
• Gupta AK, Del Rosso JQ. An evaluation of intermittent therapies used to treat onychomycosis and other dermatomycoses with the oral antifungal agents. Int. J. Dermatol. 39, 401–411 (2000).
   PubMed Web of Science ®Google Scholar
• Zais N. Pityriasis versicolor with ketoconazole. J. Am. Acad. Dermatol. 20, 703–704 (1989).
   Google Scholar
• Faergemann J, Djaru L. Tinea versicolor treatment and prophylaxis with ketoconazole. Cutis 30, 542–545 (1982).
   PubMed Web of Science ®Google Scholar
• Raush LJ, Jacobs PH. Tinea versicolor: treatment and prophylaxis with monthly administration of ketoconazole. Cutis 34, 470–471 (1984).
   PubMed Web of Science ®Google Scholar
• Gupta AK, Taborda PR, Sanzovo AD. Alternate week and combination itraconazole and terbinafine therapy for chromoblastomycosis caused by Fonsecaea pedrosoi in Brazil. Med. Mycol. 40(5), 529–534 (2002).
   PubMed Web of Science ®Google Scholar
• Terrell CL. Antifungal agents. Part II. The azoles. Mayo Clin. Proc. 74(1), 78–100 (1989).
   Google Scholar
• Grant SM, Clissold SP. Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs 37(3), 310–344 (1989).
   PubMed Web of Science ®Google Scholar
• Haria M, Bryson HM, Goa KL. Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections. Drugs 51(4), 585–620 (1996).
   PubMed Web of Science ®Google Scholar
• DeDoncker, Scher RK, Baran RL et al. Itraconazole therapy is effective for pedal onychomycosis caused by some nondermatophyte molds and in mixed infection with dermatophytes and molds: a multicenter study with 36 patients. J. Am. Acad. Dermatol. 36, 173–177 (1997).
   PubMed Web of Science ®Google Scholar
• Kumarasinghe SP, Kumarasinghe MP. Itraconazole pulse therapy in chromoblastomycosis. Eur J. Dermatol. 10(3), 220–222 (2000).
   PubMed Web of Science ®Google Scholar
• Vanden Bossche H, Dromer F, Improvisi I et al. Antifungal drug resistance in pathogenic fungi. Med. Mycol. 36(Suppl. 1), 119–128 (1998).
   PubMed Web of Science ®Google Scholar
• Mattieu L, DeDoncker P, Cauwenbergh G et al. Itraconazole penetrates the nail via the nail matrix and nail bed – an investigation in onychomycosis. Clin. Exp. Dermatol. 16, 374–376 (1991).
   PubMed Web of Science ®Google Scholar
• Heykants J, Van Peer A, Van de Velde V et al. The clinical pharmacokinetics of itraconazole: an overview. Mycoses 32(Suppl. 1), 67–87 (1989).
   PubMed Web of Science ®Google Scholar
• Ginter G, De Doncker P. An intermittent itraconazole 1-week dosing regimen for the treatment of toenail onychomycosis in dermatological practice. Mycoses 41(5–6), 235–238 (1998).
   PubMed Web of Science ®Google Scholar
• Doncker PD, Gupta AK, Marynissen G, Stoffels P, Heremans A. Itraconazole pulse therapy for onychomycosis and dermatomycoses: an overview. J. Am. Acad. Dermatol. 37(6), 969–974 (1997).
   PubMed Web of Science ®Google Scholar
• Pariser DM, Pariser RJ, Ruoff G, Ray TL. Double-blind comparison of itraconazole and placebo in the treatment of tinea corporis and tinea cruris. J. Am. Acad. Dermatol. 31, 232–234 (1994).
   PubMed Web of Science ®Google Scholar
• Parent P, Decroix J, Heenon M. Clinical experience with short schedules of itraconazole in the treatment of tinea corporis and tinea cruris. Dermatology 189, 378–381 (1994).
   PubMed Web of Science ®Google Scholar
• Tausch I, Decroix J, Gwiezdzinski Z et al. Short-term itraconazole versus terbinafine in the treatment of tinea pedis or manus. Int. J. Dermatol. 37(2), 140–142 (1998).
   PubMed Web of Science ®Google Scholar
• Ginter G. Microsporum canis infections in children: results of a new oral antifungal therapy. Mycoses 39, 265–269 (1996).
   PubMed Web of Science ®Google Scholar
• Schauder S. Itraconazole in the treatment of tinea capitis in children. Case reports with long-term follow-up evaluation. Review of the literature. Mycoses 45, 1–9 (2001).
   Google Scholar
• Hickman JG. A double-blind, randomized, placebo-controlled evaluation of short-term treatment with oral itraconazole in patients with tinea versicolor. J. Am. Acad. Dermatol. 34, 785–787 (1996).
   PubMed Web of Science ®Google Scholar
• Bradbury BD, Jick SS. Itraconazole and fluconazole and certain rare, serious adverse events. Pharmacotherapy 22(6), 697–700 (2002).
   PubMed Web of Science ®Google Scholar
• Castellsague J, Garcia-Rodriguez LA, Duque A, Perez S. Risk of serious skin disorders among users of oral antifungals: a population-based study. BMC Dermatol. 2(1), 14 (2002).
   PubMedGoogle Scholar
• Van Cauteren H, Lampo A, Vandenberghe J et al. Safety aspects of oral antifungal agents. Br. J. Clin. Pract. Suppl. 71, 47–49 (1990).
   PubMedGoogle Scholar
• Advisory for fungal drugs. FDA Consum. 35, 4 (2001).
   Google Scholar
• Ruiz-Contreras J, Rodriguez R, Gomez de Quero P et al. Severe hypokalemia and rhabdomyolysis associated with itraconazole therapy. Pediatr. Infect. Dis. J. 22(11), 1024–1025 (2003).
   PubMed Web of Science ®Google Scholar
• Martinez-Alonso JC, Dominguez-Ortega FJ, Fuentes-Gonzalo MJ. Urticaria and angioedema due to itraconazole. Allergy 58(12), 1317–1318 (2003).
   PubMed Web of Science ®Google Scholar
• Nagaoka Y, Okochi H, Tamaki K. Leukocytopenia after administration of itraconazole. Mycoses 46(5–6), 240–241 (2003).
   PubMed Web of Science ®Google Scholar
• Alvarez-Fernandez JG, Castano-Suarez E, Cornejo-Navarro P et al. Photosensitivity induced by oral itraconazole. J. Eur. Acad. Dermatol. Venereol. 14(6), 501–503 (2000).
   PubMed Web of Science ®Google Scholar
• Ahmad SR, Singer SJ, Leissa BG. Congestive heart failure associated with itraconazole. Lancet 357(9270), 1766–1767 (2001).
   PubMed Web of Science ®Google Scholar
• Horst HA, Parwaresch R, Loffler H. Thrombocytopenia and leukopenia associated with itraconazole. Ann. Intern. Med. 125(2), 156–157 (1996).
   PubMed Web of Science ®Google Scholar
• De Doncker P, Gupta AK, Cel Rosso JQ et al. Safety of itraconazole pulse therapy for onychomycosis. An update. Postgrad. Med. 17–25 (1999).
   PubMedGoogle Scholar
• Wolf R, Wolf D, Kuperman S. Focal nodular hyperplasia of the liver after itraconazole treatment. J. Clin. Gastroenterol. 33(5), 418–420 (2001).
   PubMed Web of Science ®Google Scholar
• Goto Y, Kono T, Teramae K, Ishii M. Itraconazole-induced drug eruption confirmed by challenge test. Acta Derm. Venereol. 80(1), 72 (2000).
   PubMed Web of Science ®Google Scholar
• Talwalkar JA, Soetikno RE, Carr-Locke DL, Berg CL. Severe cholestasis related to itraconazole for the treatment of onychomycosis. Am. J. Gastroenterol. 94(12), 3632–3623 (1999).
   PubMed Web of Science ®Google Scholar
• Nguyen AJ, Nelson DB, Thurn JR. Pseudomembranous colitis after itraconazole therapy. Am. J. Gastroenterol. 94(7), 1971–1973 (1999).
   PubMed Web of Science ®Google Scholar
• Nelson MR, Smith D, Erskine D, Gazzard BG. Ventricular fibrillation secondary to itraconazole induced hypokalemia. J. Infect. 26(3), 348 (1993).
   PubMed Web of Science ®Google Scholar
• Linthoudt H, van Raemdonck D, Lerut T et al. The association of itraconazole and methylprednisilone may give rise to important steroid-related side effects. J. Heart Lung Transplant. 15, 1165 (1996).
   PubMed Web of Science ®Google Scholar
• Kaukonen KM, Olkkola KT, Neuvonen PJ. Itraconazole increases plasma concentrations of quinidine. Clin. Pharmacol. Ther. 62, 510–517 (1997).
   PubMed Web of Science ®Google Scholar
• Gillies J, Hung KA, Fitzsimons E, Soutar R. Severe vincristine toxicity in combination with itraconazole. Clin. Lab. Haematol. 20(2), 123–124 (1998).
   PubMedGoogle Scholar
• Ariffin H, Omar KZ, Ang EL, Shekhar K. Severe vincristine neurotoxicity with concomitant use of itraconazole. J. Paediatr. Child Health 39(8), 638–639 (2003).
   PubMed Web of Science ®Google Scholar
• Meunier F. Fluconazole treatment of fungal infections in the immunocompromised host. Semin. Oncol. 17(3 Suppl. 6), 19–23 (1990).
   PubMed Web of Science ®Google Scholar
• Kauffman CA, Carver PL. Antifungal agents in the 1990s. Current status and future developments. Drugs 53(4), 539–549 (1997).
   PubMed Web of Science ®Google Scholar
• Pasko MT, Piscitelli SC, Van Slooten AD. Fluconazole: a new triazole antifungal agent. DICP 24(9), 860–867 (1990).
   PubMedGoogle Scholar
• Kowalsky SF, Dixon DM. Fluconazole: a new antifungal agent. Clin. Pharm. 10(3), 179–194 (1991).
   PubMedGoogle Scholar
• Faergemann J. Pharmacokinetics of fluconazole in skin and nails. J. Am. Acad. Dermatol. 40, S14–S20 (1999).
   PubMed Web of Science ®Google Scholar
• Scher RK, Brennerman D, Rich P et al. A placebo-controlled, randomized, double-blind trial of once weekly fluconazole (150mg, 300mg, 400mg) in the treatment of distal subungal onychomycosis of the toenail. J. Am. Acad. Dermatol. 38, S77–S86 (1998).
   Google Scholar
• Drake L, Babel D, Stewart DM et al. Once-weekly fluconazole (150, 300 or 400mg) in the treatment of distal subungal onychomycosis of the fingernail. J. Am. Acad. Dermatol. 38, S87–S94 (1998).
   PubMedGoogle Scholar
• Havu V, Heikkila H, Kuokkanen K et al. A double-blind, randomized study to compare the efficacy and safety of terbinafine (Lamisil) with fluconazole (Diflucan) in the treatment of onychomycosis. Br. J. Dermatol. 142(1), 97–102 (2000).
   PubMed Web of Science ®Google Scholar
• Suchil P, Gei FM, Robles M et al. Once-weekly oral doses of fluconazole 150 mg in the treatment of tinea corporis/cruris and cutaneous candidiasis. Clin. Exp. Dermatol. 17, 397–401 (1992).
   PubMed Web of Science ®Google Scholar
• Montero-Gei F, Perera A. Therapy – fluconazole for tinea corporis, tinea cruris, and tinea pedis. Clin. Infect. Dis. 14(Suppl.), S77–S81 (1992).
   Web of Science ®Google Scholar
• Faergemann J. Treatment of pityriasis versicolor with single dose of fluconazole. Acta Derm. Venereol. 72, 74–75 (1992).
   PubMed Web of Science ®Google Scholar
• Amer MA. Fluconazole in the treatment of tinea versicolor. Int. J. Dermatol. 36, 940–942 (1997).
   PubMed Web of Science ®Google Scholar
• Albert SG, Deleon MJ, Silverberg AB. Possible association between high-dose fluconazole and adrenal insufficiency. Crit. Care Med. 29(3) 668–670 (2001).
   PubMed Web of Science ®Google Scholar
• Goel A, Jain C. Fluconazole induced fixed drug eruption: a rare offender. J. Dermatol. 31(4), 345–346 (2004).
   PubMed Web of Science ®Google Scholar
• Albert SG, DeLeon MJ, Silverberg AB. Possible association between high-dose fluconazole and adrenal insufficiency in critically ill patients. Crit. Care Med. 29(3), 668–670 (2001).
   PubMed Web of Science ®Google Scholar
• Shibata S, Kami M, Kanda Y et al. Acute adrenal failure associated with fluconazole after administration of high-dose cyclophosphamide. Am. J. Hematol. 66(4), 303–305 (2001).
   PubMed Web of Science ®Google Scholar
• Wong-Beringer A, Shriner K. Fluconazole-induced agranulocytosis with eosinophilia. Pharmacotherapy 20(4), 484–486 (2000).
   PubMed Web of Science ®Google Scholar
• Tiao GM, Martin J, Weber FL, Cohen RM, Hanto DW. Addisonian crisis in a liver transplant patient due to fluconazole withdrawal. Clin. Transplant. 13(1 Pt 1), 62–64 (1999).
   PubMed Web of Science ®Google Scholar
• Kalivas J. Thrombocytopenia caused by fluconazole. J. Am. Acad. Dermatol. 35(2 Pt 1), 284 (1996).
   PubMed Web of Science ®Google Scholar
• Goldsmith LA. Alopecia associated with fluconazole therapy. Ann. Intern. Med. 125(2), 153 (1996).
   PubMed Web of Science ®Google Scholar
• Kidd D, Ranaghan EA, Morris TC. Hypokalaemia in patients with acute myeloid leukaemia after treatment with fluconazole. Lancet 1(8645), 1017 (1989).
   PubMed Web of Science ®Google Scholar
• Gothard P, Rogers TR. Voriconazole for serious fungal infections. Int. J. Clin. Pract. 58(1), 74–80 (2004).
   PubMed Web of Science ®Google Scholar
• Pearson MM, Rogers PD, Cleary JD, Chapman SW. Voriconazole: a new triazole antifungal agent. Ann. Pharmacother. 37(3), 420–432 (2003).
   PubMed Web of Science ®Google Scholar
• Hoffman HL, Rathbun RC. Review of the safety and efficacy of voriconazole. Exp. Opin. Investig. Drugs 11(3), 409–429 (2002).
   PubMed Web of Science ®Google Scholar
• Denning DW, Griffiths CE. Muco-cutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazole. Clin. Exp. Dermatol. 26(8), 648–653 (2001).
   PubMed Web of Science ®Google Scholar
• Jeu LA, Piacenti FJ, Lyakhovetskiy AG, Fung HB. Voriconazole. Clin. Ther. 25(5), 1321–1381 (2003).
   PubMed Web of Science ®Google Scholar
• Gupta AK, Sauder DN, Shear NH. Antifungal agents: an overview. Part 1. J. Am. Acad. Dermatol. 30, 677–698 (1994).
   PubMed Web of Science ®Google Scholar
• Iozumi K, Hattori N, Adachi M, Kaneko T, Shimozuma M, Tamaki K. Long-term follow-up study of onychomycosis: cure rate and dropout rate with oral antifungal treatments. J. Dermatol. 28(3), 128–136 (2001).
   PubMed Web of Science ®Google Scholar
• Smith EB. History of antifungals. J. Am. Acad. Dermatol. 23, 776–778 (1990).
   PubMed Web of Science ®Google Scholar
• DeBehedette V (based on presentation by Elewski BE, Mercurio MG). Recalcitrant tinea capitis may be due to underdosing. Cos. Derm. 9(2), 57–58 (1996).
   Google Scholar
• Kubicova L, Pravda M, Buchta V, Voprsalova M, Sedlak M. Amphotericin B, its lipid formulations and conjugates with polymers. Cent. Eur. J. Public Health 12(Suppl.), S54–S56 (2004).
   PubMedGoogle Scholar
• Martino R. Efficacy, safety and cost–effectiveness of Amphotericin B Lipid Complex (ABLC): a review of the literature. Curr. Med. Res. Opin. 20(4), 485–504 (2004).
   PubMed Web of Science ®Google Scholar
• Klastersky J. Empirical antifungal therapy. Int. J. Antimicrob. Agents 23(2), 105–112 (2004).
   PubMed Web of Science ®Google Scholar
• Vermes A, Guchelaar H-J, Dankert J. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity, and drug interactions. J. Antimicrob. Chemother. 46, 171–179 (2000).
   PubMed Web of Science ®Google Scholar
• Cornely OA, Schmitz K, Aisenbrey S. The first echinocandin: caspofungin. Mycoses 45(Suppl. 3), 56–60 (2002).
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A. History of medical mycology in the U.S. Clin. Microbial. Rev. 9, 235–272 (1996).
   PubMed Web of Science ®Google Scholar
• Hazen El, Brown R. Two antifungal agents produced by a soil actinomycete. Science 112, 423 (1950).
   PubMed Web of Science ®Google Scholar
• Medoff G, Kobayashi GA. The polyenes. In: Antifungal Chemotherapy. Speller DCE (Ed.), John Wiley, Chichester, UK, 3–33 (1980).
   Google Scholar
• Dixon PN, Warin RP, English MP. Alimentary candida albicans and napkin rashes. Br. J. Dermatol. 86, 458–462 (1972).
   PubMed Web of Science ®Google Scholar
• Brennan B, Leyden JJ. Overview of topical therapy for common superficial fungal infections and the role of the new topical agents. J. Am. Acad. Dermatol. 36, S3–S8 (1997).
   Web of Science ®Google Scholar
• Saag MS, Dismuke WE. Azole antifungal agents: emphasis on new triazoles. Antimicrob. Agents Chemother. 32, 1–8 (1988).
   PubMed Web of Science ®Google Scholar
• Ritter W. Pharmacokinetics of azole compounds. In: Sterol Biosynthesis Inhibitors. Berg D, Plempel D (Eds), Ellis Horwod Ltd., Chichester, UK, 398–429 (1988).
   Google Scholar
• Gupta AK, Einarson TR, Summerbell RC et al. An overview of topical antifungal therapy in dermatomycoses a North American perspective. Drugs 55, 645–674 (1988).
   Google Scholar
• Van Cutsem JM, Thienpont D. Miconazole, a broad-spectrum antimycotic agent with antibacterial activity. Chemotherapy 17, 392–404 (1972).
   PubMed Web of Science ®Google Scholar
• Gip L. The topical treatment of pityriasis versicolor with clotrimazole. Postgrad. Med. J. 50, 59–60 (1974).
   Google Scholar
• Savin RC, Horwitz SN. Double-blind comparison of 2% ketoconazole cream and placebo in the treatment of tinea versicolor. J. Am. Acad. Dermatol. 500–503 (1986).
   PubMed Web of Science ®Google Scholar
• Patel BK, Vora SN, Dave SN. Comparative study of oral versus topical ketoconazole therapy in pityriasis versicolor. Indian J. Dermatol. Venerol. Leprol. 59, 279–280 (1993).
   Google Scholar
• Heel RC, Brogden RN, Speight TM et al. Econazole: a review of its antifungal activity and therapeutic efficacy. Drugs 16, 177–201 (1978).
   PubMed Web of Science ®Google Scholar
• Benfield P, Clissold SP. Sulconazole: a review of its antimicrobial activity and therapeutic uses in superficial dermatophytoses. Drugs 35, 143–153 (1988).
   PubMed Web of Science ®Google Scholar
• Beetens JR, Loots W, Somers Y et al. Ketoconazole inhibits the biosynthesis of leukotrienes in vitro and in vivo. Biochem. Pharmacol. 35, 83–891 (1986).
   Google Scholar
• Taieb A, Legrain V, Palmier C et al. Topical ketoconazole for infantile seborrheic dermatitis. Dermatologica 181, 26–32 (1990).
   PubMedGoogle Scholar
• Faergemann J. Treatment of seborrheic dermatitis of the scalp with ketoconazole shampoo. A double-blind study. Acta Dermatol. Venerol. 70, 171–172 (1990).
   PubMed Web of Science ®Google Scholar
• Ryder N, Dupont M. Inhibition of squalene epoxidase by allylamine antimycotic compounds: a comparative study of the fungal and mammalian enzymes. Biochem. J. 230, 765–770 (1985).
   PubMed Web of Science ®Google Scholar
• Ryder N. Specific inhibition of fungal sterol biosynthesis by SF 86–237, a new orally active allylamine derivative. Antimicrob. Agents Chemother. 27, 252–256 (1985).
   PubMed Web of Science ®Google Scholar
• Nussbaumer P, Dorfsatter G, Grassberger M et al. Synthesis and structure – activity relationships of phenyl-substituted benzylamine antifungal agents for systemic treatment. J. Med. Chem. 36, 2115–2120 (1993).
   PubMed Web of Science ®Google Scholar
• Maeda T, Takase M, Ishibashi A et al. Synthesis and antifungal activity of butenafine hydrochloride (KP-363), a new benzylamine antifungal agent. Yakugaku Zassh 111, 126–137 (1991).
   PubMed Web of Science ®Google Scholar
• Petranyi G, Ryder NS, Stutz A. Allylamine derivatives: a new class of synthetic antifungal agents inhibiting squalene epoxidase. Science 224, 1239–1241 (1984).
   PubMed Web of Science ®Google Scholar
• Hill S, Thomas R, Smith SG et al. An investigation of the parmacokinetics of topical terbinafine 1% cream. Br. J. Dermatol. 127, 396–400 (1992).
   PubMed Web of Science ®Google Scholar
• Kagawa S. Clinical efficacy of terbinafine in 629 Japanese patients with dermatomycosis. Clin. Exp. Dermatol. 14, 124–127 (1989).
   PubMed Web of Science ®Google Scholar
• Petranyi G, Meingassner JG, Mieth H. Antifungal activity of the allylamine derivative terbinafine in vitro. Antimicrob. Agents Chemother. 31, 1365–1368 (1987).
   PubMed Web of Science ®Google Scholar
• Georgopoulos A, Petranyi G, Mieth H et al. In vitro activity of naftifine, a new antifungal agent. Antimicrob. Agents Chemother. 19, 386–389 (1981).
   PubMed Web of Science ®Google Scholar
• Villars V, Jones TC. Clinical efficacy and tolerability of terbinafine – a new topical and systemic fungicidal drug for treatment of dermatomycoses. Clin. Exp. Dermatol. 14, 124–127 (1989).
   PubMed Web of Science ®Google Scholar
• Vanden Bossche H, Willemsens G, Cools W et al. Biochemical effects of miconazole on fungi. II. Inhibition of ergosterol biosynthesis in Candida albicans. Chem. Biol. Interact. 21, 59–78 (1978).
   PubMed Web of Science ®Google Scholar
• Evans EG, James IG, Seaman RA et al. Does naftifine have anti-inflammatory properties? A double-blind comparative study with 1% clotrimazole/1% hydrocortisone in clinically diagnosed infections of the skin. Br. J. Dermatol. 129, 437–442 (1983).
   Google Scholar
• Nahm WK, Orengo I, Rosen T. The antifungal agent butenafine manifests anti-inflammatory activity in vivo. J. Am. Acad. Dermatol. 41, 203–206 (1999).
   PubMed Web of Science ®Google Scholar
• HY. Recent Progress in Antifungal Therapy. Marcel Dekker, NY, USA (1992).
   Google Scholar
• Riviera L, Bellotti M. Lab evaluation of ciclopirox olamine. In vitro and in vivo studies on its antimicrobial activity. Chemotherapy 2, 97–102 (1983).
   Google Scholar
• Aly R, Bagatell R, Dittmas W et al. Ciclopirox olamine lotion 1% bioequivalence to ciclopirox olamine cream 1% and clinical efficacy in tinea pedis. Clin. Ther. 11, 290–303 (1989).
   PubMed Web of Science ®Google Scholar
• Baran R, Tosti A, Piraccini BM. Uncommon clinical patterns of Fusarium nail infection: report of three cases. Br. J. Dermatol. 139, 424–427 (1997).
   Google Scholar
• Abrams B, Heinz H, Hoehler T. Ciclopirox olamione: A hydroxypyridone antifungal agent. Clin. Dermatol. 9, 471–477 (1992).
   Web of Science ®Google Scholar
• Gupta AK, Bluhm R. Ciclopirox (Loprox) gel for superficial fungal infections. Skin. Ther. Lett. 9, 4–5 (2004).
   Google Scholar
• Gupta AK, Sauder DN, Shear NH. Antifungal agents: an overview. Part I. J. Am. Acad. Dermatol. 30, 677–700 (1994).
   PubMed Web of Science ®Google Scholar
• Bohn M, Kraemer KT. Dermatopharmacology of ciclopirox nail lacquer 8% for the topical treatment of onychomycosis. J. Am. Acad. Dermatol. 43, S57–S69 (2000).
   PubMed Web of Science ®Google Scholar
• Gupta AK. Pharmacoeconomics analysis of ciclopirox nail lacquer solution 8%; the new oral antifungal agents used to treat dermatophyte toenail onychomycosis in the US. J. Am. Acad. Dermatol. 43, S81–S95 (2000).
   PubMed Web of Science ®Google Scholar
• Polak-Wyss A. Mechanism of action of antifungals and combination therapy. J. Eur. Acad. Dermatol. Venerol. 4(Suppl.), 511–516 (1995).
   Google Scholar
• Ghannoum MA. Future of antimycotic therapy. Dermatol. Ther. 3, 104–111 (1997).
   Google Scholar
• Rezabek GH, Friedman AD. Superficial fungal infections of the skin. Diagnosis and current treatment recommendations. Drugs 43, 674–682 (1992).
   PubMed Web of Science ®Google Scholar
• Danby FW, Maddin WS, Margesson LJ et al. A randomized placebo controlled trial of ketoconazole 2% shampoo versus selenium sulfide 2.5% shampoo in the treatment of moderate to severe dandruff. J. Am. Acad. Dermatol. 29, 1008–1012 (1993).
   PubMed Web of Science ®Google Scholar
• Sanchez JL, Torres VM. Double-blind efficacy study of selenium sulfide in tinea versicolor. J. Am. Acad. Dermatol. 11, 235–238 (1984).
   PubMed Web of Science ®Google Scholar
• Allen HB, Honig PJ, Leyden JJ et al. Selenium sulfide: adjunctive therapy for tinea capitis. Pediatrics 69, 81–83 (1982).
   PubMed Web of Science ®Google Scholar
• Elewski BE, Haley HR, Robbins CM. The use of 40% urea cream in the treatment of moccasin tinea pedis. Cutis 73, 355–357 (2004).
   PubMed Web of Science ®Google Scholar
• Grant SM, Clissold SP. Itraconazole: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in superficial and systemic mycoses. Drugs 37, 310–344 (1989).
   PubMed Web of Science ®Google Scholar
• Gebhart R, Espinel-Ingroff A, Shadomyh S. In vitro susceptibility studies with oxiconazole (Ro13–8996). Chemotherapy 30, 244–247 (1984).
   PubMed Web of Science ®Google Scholar
• Have RS, Loebenberg D. Animal models in the search for antifungal agents. Am. Soc. Microbiol. News 54, 235–239 (1988).
   Google Scholar
• Arika T, Yokoo M, Hase T et al. Effects of butenafine hydrochloride, a new benzylamine derivative, on experimental dermatophytosis in guinea pigs. Antimicrob. Agents Chemother. 34, 2250–2253 (1990).
   PubMed Web of Science ®Google Scholar
• Pershing LK, Corlett J, Jorgensen C. In vivo pharmacokinetics and pharmacodynamics of topical ketoconazole and miconazole in human stratum corneum. Antimicrob. Agents Chemother. 38, 90–95 (1994).
   PubMed Web of Science ®Google Scholar
• Hart R, Bell-Syer SEM, Crawford F, Torgerson DJ, Young P, Russell I. Systematic review of topical treatments for fungal infections of the skin and nails of the feet. Br. Med. J. 319, 79–82 (1999).
   PubMed Web of Science ®Google Scholar
• Millikan LE, Galen WK, Gewirtzman GB et al. Naftifine cream 1% versus econazole cream 1% in the treatment of tinea cruris and tinea corporis. J. Am. Acad. Dermatol. 18, 52–56 (1988).
   PubMed Web of Science ®Google Scholar
• Saple DG, Aman AK, Ravichandran G, Korde KM, Desai A. Efficacy and safety of butenafine in superficial dermatophytoses (tinea pedis, tinea cruris, tinea corporis). J. Indian. Med. Assoc. 99, 274–275 (2001).
   PubMedGoogle Scholar
• Arika T, Hase T, Yokoo M. Anti-trichophyton mentagrophytes activity and percutaneous permeation of butenafine in guinea pigs. Antimicrob. Agents Chemother. 37, 363–365 (1993).
   PubMed Web of Science ®Google Scholar
• Bergstresser PR, Elewski B, Hanifin J et al. Topical terbinafine and clotrimazole in interdigital tinea pedis: a multicenter comparison of cure and relapse rates with one and four week treatment regimens. J. Am. Acad. Dermatol. 28, 648–651 (1993).
   PubMed Web of Science ®Google Scholar
• Georgopapadakou NH, Bertasso A. Effects of squalene epoxidase inhibitors on Candida albicans. Antimicrob. Agents Chemother. 36, 1779–1781 (1992).
   PubMed Web of Science ®Google Scholar
• Flagothier C, Pierard-Franchimont C, Pierard GE. New insights into the effect of amorolfine nail lacquer. Mycoses 48(2), 91–4 (2005).
   PubMed Web of Science ®Google Scholar
• Rich P, Scher RK, Breneman D, Savin RC. Pharmacokinetics of three doses once weekly fluconazole (150, 300, 450 mg in distal subungualonychomycosis of the toenail. J. Am. Acad. Dermatol. 38(6 Pt 2), S103–S109 (1998).
   Google Scholar
• Rich P, Scher RK, Breneman D, Savin RC. Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungualonychomycosis of the fingernail. J. Am. Acad. Dermatol. 38, S87–S94 (1998)
   Google Scholar
• Scher RK, Breneman D, Rich P, Savin RC. Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungualonychomycosis of the toenail. J. Am. Acad. Dermatol. 38, S77–S86 (1998).
   Google Scholar